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The work described in this dissertation started in 2013 and focuses on the activation of 
cap-dependent mRNA translation and regulation of the translation inhibitor protein 4E-
BP1 during mitosis. By investigating the viral oncoprotein Merkel cell polyomavirus 
small T antigen (MCV sT), an alternative pathway for cap-dependent mRNA translation 
regulation through the CDK1 kinase was discovered. In addition, a novel 
phosphorylation site of 4E-BP1—Ser83—was identified in mitotic cells, and a polyclonal 
antibody against this phosphorylation site was generated. The phospho-Ser83 4E-BP1 
antibody is a useful tool that can be used as a bona fide mitotic marker by various 
assays: immunoblotting, immunofluorescence, and flow cytometry. Overall, this work 
provokes a reassessment of protein synthesis regulation during cell division, hints at 
additional undescribed functions for 4E-BP1, and suggests that certain mRNAs 
translated in this phase of the cell cycle may contribute to cell proliferation and 
tumorigenesis.  
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1.0  INTRODUCTION 
1.1 REGULATION OF TRANSLATION INITIATION 
Eukaryotic messenger RNA (mRNA) translation is a complex process that is tightly 
regulated by various protein and non-protein components. mRNA translation undergoes 
regulation at each of its four distinct phases: initiation, elongation, termination, and 
ribosome recycling (1). Translation initiation is the most highly regulated and 
complicated phase, and thus, it is the rate-limiting step (2). It requires the highest 
number of protein factors in order to recruit the ribosome to the mRNA for protein 
synthesis (2). The 80S ribosome is assembled on the message through a canonical 
series of events as follows: mRNA 5’ cap binding by the eukaryotic initiation factor 4F 
(eIF4F) complex, 43S pre-initiation complex (PIC) formation, 40S ribosome recruitment 
to mRNA, start codon localization, and 60S ribosome joining. This introduction reviews 
the regulation of translation initiation and the role of the eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1) in the context of cell cycle progression and viral and non-
viral induced tumorigenesis. 
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1.2 MECHANISMS OF TRANSLATION INITIATION 
In eukaryotic organisms, most mRNA translation follows the canonical cap-dependent 
mechanism of translation (3). A portion of cellular mRNAs rely on alternative 
mechanisms that bypass the canonical requirements for translation initiation (4, 5). 
Nonetheless, the objective of all these mechanisms is the same—recruiting the 
ribosome to the 5’ untranslated region to begin the synthesis of functional proteins. 
1.2.1 Cap-Dependent Translation 
Cap-dependent translation is the main mechanism by which most mRNAs are 
translated in eukaryotic cells. The term “cap-dependent” refers to the first step in this 
mechanism, where the translation initiation factors assemble at the 5’ cap of an mRNA 
and form the eukaryotic initiation factor 4F (eIF4F) complex (Figure 1). The cap-binding 
protein eIF4E directs translation initiation complex assembly at the 5’ untranslated 
region (5’ UTR) of an mRNA (6, 7). The 5’ cap-bound eIF4E protein then recruits the 
essential eIF4G protein, which serves as a large scaffold for the various cap complex 
members (8, 9). This scaffold protein performs several functions: it binds eIF4A, an 
RNA helicase that resolves secondary RNA structures near the 5’-cap (10); it recruits 
the 43S pre-initiation complex (containing the 40S ribosome subunit, initiator Met-tRNA, 
and ribosome binding proteins eIF2 and eIF3) (11-18); and it circularizes and facilitates 
translation of mRNA by interacting with the 3’ end poly-adenine (poly(A)) binding protein 
(PABP) (19, 20). The 43S pre-initiation complex then scans the 5’ UTR, in the 5’ to 3’ 
direction, to find the start codon and attract the 60S ribosomal subunit to initiate 
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translation (21). The translation initiation factors dissociate from the 40S ribosomal 
subunit and allow it to complex with the 60S subunit, forming the full 80S ribosome 
loaded with the initiation Met-tRNA (10). Polypeptide chain elongation begins with the 
addition of amino acids to the start methionine at the AUG codon, and peptide synthesis 
is terminated when the 80S ribosome meets a stop codon (21). 
 
 
Figure 1. Mechanism of Cap-Dependent mRNA Translation 
Cap-dependent mRNA translation is initiated by the formation of the eIF4F complex on 
the 5’ cap of mRNA, which recruits the 43S pre-initiation complex that forms between 
the 40S ribosomal subunit, eIF2, and eIF3. The full initiation complex scans for the first 
start codon and recruits the 60S ribosomal subunit upon encountering it, forming the 
80S ribosome to begin translation (From López-Lastra et al. 2005 (22)). 
1.2.2 Cap-Independent Translation 
Internal Ribosome Entry Site (IRES)-Mediated Translation 
Some mRNAs are not translated through the cap-dependent translation mechanism and 
rely mainly on internal ribosome entry site (IRES)-mediated translation. IRESes are 
structured RNA elements found at 5’ UTRs that allow mRNAs to be translated through 
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an alternative mechanism under conditions that suppress cap-dependent protein 
synthesis, such as viral infection (23-25), stress (26, 27), apoptosis (28), and mitosis 
(29, 30).  
While most eukaryotic transcripts contain a 5’ cap and a poly(A) tail, IRES-
containing cellular mRNAs are mainly translated through IRES-mediated translation but 
can also be translated, albeit less efficiently, through cap-dependent translation (31-33). 
First identified in the single-stranded positive-sense RNA poliovirus genome, IRES 
structures at mRNA 5’ UTRs recruit the ribosome and some translation initiation factors 
internally, bypassing the translation initiation complex eIF4F that forms at the 5’ cap 
(Figure 2) (23, 34). Some proto-oncogenes contain 5’ IRES sequences, such as c-Myc 
(35, 36), ornithine decarboxylase (ODC) (30), vascular endothelial growth factor (VEGF) 
(26), X-linked inhibitor of apoptosis (XIAP) (28), and fibroblast growth factor 2 (FGF-2) 
(37), which allow them to overcome cap-dependent translation regulation. 
The requirements for IRES-mediated translation vary across cellular and viral 
transcripts. Despite their similarities in function, IRES elements are not homologous in 
sequence nor structure and initiate translation by recruiting a plethora of different 
canonical and non-canonical factors (4, 38). A group of RNA-binding proteins, called 
IRES-trans-acting factors (ITAFs), are also reported to stimulate this translation 




Figure 2. Internal Ribosome Entry Site (IRES) Mediated Translation 
Internal translation initiation permits the 43S pre-initiation complex to be recruited 
directly to the structured 5’ UTR of some cellular mRNAs, circumventing the 5’ cap 
complex. Different IRESes require different translation initiation factors and ITAFs, to 
aid in their function to attract the ribosome and any other translation initiation 
components other than eIF4E (From López-Lastra et al. 2005 (22)). 
 
 
N6-methyladenosine (m6A)-Mediated Translation 
A novel mechanism for eukaryotic translation initiation—N6-methyladenosine-mediated 
translation—has been proposed in recent years. Similar to IRES structures, N6-
methyladenosine (m6A) modifications in mRNA can also initiate translation internally by 
recruiting the ribosome to the message. m6A is the most abundant internal modification 
in the mammalian transcriptome, found predominantly in the 3’ UTR of more than 7,000 
human transcripts (40, 41). In 2015 Wang et al. reported that m6A modifications in the 
3’ UTR provide a binding site for the YTH domain-containing protein YTHDF1 (42). 
YTHDF1 interacts with eIF3 and thus attracts the 43S pre-initiation complex directly to 
the 5’ UTR, forming a closed-loop mRNA structure (42). A couple of concurrent studies 
showed that uncapped mRNAs containing a single m6A in their 5’ UTR can be 
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translated in vitro unlike their unmodified counterparts (5, 43). m6A modifications 
located in the 5’ UTR of mRNAs provide a binding site for eIF3, which can be reversed 
by overexpression of the mRNA demethylase FTO and knockdown of the N6-
adenosine-methyltransferase METTL3 (5, 43, 44). Furthermore, mRNA with 5’ UTR 
m6A modifications can still be translated efficiently under heat stress conditions that 
suppress cap-dependent translation (43). This novel mechanism of mRNA translation 
initiation suggests that alternative mechanisms, besides IRES-mediated translation, 
take over protein synthesis control under abnormal cellular conditions and allow cells to 


















1.3 CIS-ACTING RNA FACTORS 
Translation initiation efficiency is regulated by the intrinsic composition of the mRNA 
(cis-acting factors) and initiation protein factor availability (trans-acting factors) (10, 45-
49). Cis-acting features outside of the mRNA main open reading frame (ORF), such as 
the 7-methyl-guanine cap, poly-adenine tail, and 5’ and 3’ UTRs (Figure 3), contain 
primary sequence and secondary structure elements that control its accessibility to the 
eIF4F complex and can be unique to the message or family of messages (45).  
 
 
Figure 3. Anatomy of a Eukaryotic Messenger RNA 
Eukaryotic mRNAs are modified post-transcriptionally with a 7-methyl-guanine cap at 
the 5’ end and with a poly-adenine tail at the 3’ end. The protein coding sequence is 
found in a region called the main ORF, which begins at the AUG start codon and ends 
with a stop codon, UGA, UAA, or UAG. The 5’ and 3’ UTRs flank the main ORF. 
1.3.1 5’ 7-Methyl-Guanine Cap and 3’ Poly-Adenine Tail 
Mature cellular mRNAs contain a 7-methyl-guanine cap structure at their 5’ end (50, 
51), which is added post-transcriptionally by the RNA guanylyltransferase 5′ 
triphosphatase RNGTT and the RNA guanine-7-methyltransferase RNMT (52-54). The 
7-methyl-guanine cap serves multiple purposes: it protects the message from 5’ 
exonuclease-mediated degradation (55, 56), facilitates nuclear export (57-59), 
increases polyadenylation efficiency (60), and attracts the translation initiation complex 
(7). The eukaryotic initiation factor 4E (eIF4E) binds this cap structure and attracts the 
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trans-acting elements required to start translation (7, 61). The 5’ cap consists of a 
guanine nucleotide methylated at the 7’ position (62) and connected to the mRNA by a 
5’-to-5’ triphosphate linkage (63). While the 7-methyl-guanine cap is necessary for 
efficient mRNA translation, it is dispensable in some mRNAs that rely on other structural 
features to recruit the ribosome (64). 
Another post-transcriptional modification found in mature mRNAs is the poly-
adenine (poly(A)) tail, which is added on the 3’ end of all cellular transcripts but those 
encoding histones (65). Like the 5’ cap structure, the poly(A) tail protects mRNA from 
exonuclease-mediated degradation and enhances translation by interacting with the 5’ 
cap-associated eukaryotic initiation factor 4G (eIF4G) protein through the poly(A)-
binding protein (PABP) (19, 66, 67). This interaction forms a stable closed-loop mRNA 
structure that facilitates translation in vitro (20, 68, 69). 
1.3.2 Untranslated Regions 
Translation begins when the ribosome recognizes the first AUG triplet on the mRNA, 
termed the start codon. Although the rate of translation initiation depends largely on the 
availability of trans-acting initiation factors that allow the ribosome to find the start codon 
(70), sequence and structural features in the non-coding regions can also determine 
how efficiently an mRNA is translated (71, 72).   
 
Sequence 
The length and composition of the 5’ UTR affects the translation efficiency of a 
message. The shorter the 5’ UTR of an mRNA is, the more efficiently it can be 
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translated by the ribosome (73). The nucleotide sequence composition of the 5’ UTR 
can also affect mRNA translation efficiency. For instance, genes that are critical for 
protein synthesis and ribosomal biogenesis contain a short stretch of pyrimidine 
nucleotides at the beginning of their 5’ UTR that facilitates their translation (74). This 
sequence, called the 5’ terminal oligopyrimidine (TOP) motif, is composed of 6-12 
pyrimidines at the 5’ end of the mRNA (75). Transcripts encoding translation initiation 
and elongation factors and ribosomal proteins are known to contain 5’ TOP motifs (76-
78). These are reported to be mainly sensitive to cell proliferation signaling by mTORC1 
(79, 80). When mTORC1 signaling is inhibited pharmacologically, the levels of proteins 
translated from 5’ TOP-containing mRNAs decreases. 
Another regulatory sequence found in the 5’ UTR, upstream open reading frames 
(uORFs) prevent translation of the downstream main ORF (81). Normally, eukaryotic 
translation begins at the first AUG start codon found in the optimal Kozak consensus 
sequence context GCC(A/G)CCAUGG (21, 82, 83). Transcripts that contain uORFs, on 
the other hand, initiate translation through alternative start codons, mainly the cognate 
CUG triplet (21, 84, 85). The primary function of uORFs seems to be reducing the 
synthesis of physiologically functional proteins by encoding short non-functional 
peptides that are 5-30 amino acids in length (81). 
The 3’ UTR is another regulatory region located downstream of the protein 
coding sequence of every mRNA, which includes the poly(A) tail (2, 86, 87). While the 5’ 
UTR plays a prominent role in regulating translation initiation, the 3’ UTR regulates 
primarily the stability of the mRNA (87). The only clear impact that the 3’ UTR may have 
on translation initiation is through the poly(A) tail. This tract of adenines provides a 
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binding site for several PABP molecules (68), which enhance in vitro translation 
initiation by interacting with the 5’ cap complex protein eIF4G (88). 
 
Structure 
Secondary RNA structures at the 5’ UTR also regulate translation initiation. Secondary 
structures form when complementary regions of RNA form base pairs and adopt stable 
hairpin structures (89). These structures sterically hinder the 43S ribosome pre-initiation 
complex from finding the start codon since the 40S ribosome subunit can only 
accommodate single-stranded RNA (89, 90). In order to translate highly structured 5’ 
UTR mRNAs, the translation initiation complex relies on the activity of its RNA helicase 
eIF4A to resolve the secondary structures, which retards the ribosome from reaching 
the start codon and thus decreases the translation rate of the mRNA (10).  
Some mRNAs, on the other hand, possess an IRES structure that permits their 
translation by an alternative process. This specialized secondary RNA structure allows 
capped or uncapped mRNAs to recruit the translation machinery to an internal site 
upstream of their coding region, bypassing the translation initiation complex assembled 
at their 5’ end (23, 91-93). IRES elements are present in the 5’ UTR of 3-5% of all 
cellular mRNAs (64, 94). Secondary structures have also been identified in the 3’ UTR 
of various transcripts, but whether they affect translation initiation is unknown (95). 
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1.4 TRANS-ACTING PROTEIN FACTORS 
Translation initiation is also regulated by trans-acting factors, which mainly consist of 
the eukaryotic initiation factor 4 (eIF4) proteins eIF4E, eIF4G, and eIF4A (1). Together 
these three proteins and several other accessory proteins form the eIF4F translation 
initiation complex and are responsible for recruiting the ribosome to the mRNA. The 
molecular interactions between these proteins and the 5’ UTR of mRNAs are modular 
and allow for rapid regulation of gene expression (2).  
1.4.1 Eukaryotic Initiation Factor 4E  
The eukaryotic initiation factor 4E (eIF4E) is the eIF4F complex protein that interacts 
directly with the 7-methyl-guanine cap at the 5’ end of mRNA (7). eIF4E has a molecular 
weight of 24 kDa, and it is the least abundant translation initiation factor and thus the 
limiting one (6). eIF4E is highly conserved in eukaryotic organisms, and mammalian 
organisms possess three isoforms: eIF4E-1 (eIF4E), eIF4E-2 (or 4EHP), and eIF4E-3 
(96). eIF4E-1 is the predominant 4E family member and binds to the 5’ cap with much 
higher affinity than eIF4E-2 and eIF4E-3 (97, 98). Thus, eIF4E-1 is the most studied 
cap-binding protein and is simply referred to as eIF4E. 
The cap-binding protein eIF4E has two main binding partners: the eukaryotic 
initiation factor 4G (eIF4G) and the eukaryotic initiation factor 4E binding proteins (4E-
BPs) (99, 100). The canonical binding site for eIF4G and 4E-binding proteins (4E-BPs) 
is found on the eIF4E dorsal region, near residue W73 of human eIF4E (101). When 
this residue is mutated to alanine, the interaction with eIF4G is completely ablated and 
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the translation initiation complex cannot assemble on the cap structure (101). Unlike 
eIF4E-1, eIF4E-2 cannot interact with eIF4G and eIF4E-3 cannot interact with 4E-BPs 
(96). Given its inability to associate with eIF4G, eIF4E-2 is suspected to inhibit mRNA 
translation by competing with eIF4E-1 for cap-binding. A recent study has shown that 3’ 
UTR-associated RNA-induced silencing complexes (RISCs) recruit eIF4E-2 to the 5’ 
cap through the deadenylating complex CCR4-NOT, forming a closed-loop structure 
that inhibits the translation initiation complex assembly (102).  
The interaction between eIF4E and eIF4G is inhibited by the 4E-BPs, which are 
molecular mimics of eIF4G (100, 103). Sharing the conserved eIF4E binding sequence 
as is found in eIF4G, YXXXXLΦ (where X is any amino acid residue and Φ is a 
hydrophobic residue) (100), 4E-BPs (4E-BP1-3) compete with eIF4G for eIF4E 
occupancy on the dorsal binding pocket and prevent the formation of the translation 
initiation complex, thereby inhibiting protein synthesis (103, 104). In addition to 
interacting with eIF4E dorsally, 4E-BP1 binds the lateral surface of eIF4E through a 
novel motif consisting of residues 79PGVTS83 (105-107).  
eIF4E engages the 5’ cap of mRNA through two tryptophan residues, W56 and 
W102, located on its ventral side (101). Mutation of W56 to alanine abolishes eIF4E 
interaction with the 5’ cap structure (101). eIF4G binding to eIF4E seems to 
allosterically increase the affinity of eIF4E for the 5’ cap. Studies in yeast have shown 
that interaction with eIF4G induces a conformational change in eIF4E that tightens its 
grip on the 7-methyl-guanine cap (108, 109).  
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1.4.2 Eukaryotic Initiation Factor 4G 
The eukaryotic initiation factor protein 4G (eIF4G) is the largest protein in the eIF4F 
complex and serves as a scaffold with docking sites for the multiple proteins that make 
up the translation initiation complex (110-113). It has a molecular weight of 220 kDa 
(114), and it binds eIF4E, the RNA helicase eIF4A, the poly(A) binding protein PABP, 
and eIF3, which connects the eIF4F-mRNA complex to the 43S ribosome pre-initiation 
complex (110). In mammals, two functionally redundant eIF4G isoforms exist, eIF4G I 
and eIF4G II. Two smaller eIF4G isoforms also exist—the PABP interacting protein-1 
(Paip-1) and the death-associated protein-5 (Dap-5)—that lack the conserved eIF4E 
binding site and only share homologous eIF4A and eIF3 binding sites (110). The former 
has been shown to bind eIF3 and enhance translation initiation (9, 115), while the latter 
appears to promote IRES-mediated translation (116). 
eIF4G has multiple docking sites for protein factors necessary for translation 
initiation activation (Figure 4). The N-terminus of the eIF4G protein contains the binding 
sites for eIF4E and PABP (117-119). The eIF4E binding site is located in this region at 
amino acids 572-578, and its human sequence is the conserved YDREFLL (100). The 
PABP binding site is located at amino acids 172-200 (120), and allows the 5’ end-
associated eIF4G to form a closed-loop mRNA structure with the 3’ poly(A)-bound 
PABP proteins (19, 20). Circularization of mRNA by the eIF4G-PABP interaction 
enhances mRNA translation in vitro, but this has yet to be confirmed in vivo.  
Like many other large complex scaffold proteins, eIF4G possesses multiple 
HEAT (Huntingtin, EF3, PP2A, and TOR) repeats located in its central and C-terminal 
regions (Figure 4) (121). These fragments encompass binding sites for the eukaryotic 
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initiation factor 4A (eIF4A) between amino acids 650-1000 and amino acids 1200-1400 
(8, 118, 122), the eukaryotic initiation factor 3 (eIF3) between amino acids 1000-1100 
(8, 11), and the MNK1/2 kinases between amino acids 1400-1600 (123, 124). 
Interaction of eIF4G to the RNA helicase eIF4A aids in resolving secondary RNA 
structures in the 5’ UTR (125), while interaction with eIF3 recruits the 40S ribosome 
subunit (9). eIF4G recruits the MNK1/2 kinases through its C-terminal end to 
phosphorylate cap-bound eIF4E at S209, whose function remains unclear (123, 124). 
Additionally, eIF4G is also able to bind RNA directly through a central RNA recognition 
motif (RRM) that lies between amino acids 740-940 (25, 111).  
 
 
Figure 4. Architecture of the Scaffold Protein eIF4G 
The schematic shows the amino acid positions of the various binding sites on eIF4G for 
PABP, eIF4E, eIF3, eIF4A, and MNK1/2 kinases located at HEAT repeats, and for RNA 
at the RNA recognition motif (RRM). 
1.4.3 Eukaryotic Initiation Factor 4A 
eIF4A is the only member of the eIF4F complex possessing enzymatic activity—RNA-
dependent ATPase activity (126). It has a molecular weight of 46 kDa (127), and it acts 
as an RNA helicase. eIF4A unwinds secondary RNA structures at the 5’ UTR of mRNA 
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to permit ribosome binding and scanning for the start codon (128-131). In mammals, 
there are three eIF4A isoforms—eIF4A I, eIF4A II, and eIF4A III—which are members of 
the Aspartate-Glutamine-Alanine-Aspartate (DEAD)-box family (132-134). The first two, 
eIF4A I and eIF4A II, are functionally redundant and homologous (135). eIF4A interacts 
with eIF4G through a recombinase A-like domain located in its C-terminus (136). By 
stabilizing the interaction of eIF4A with RNA, eIF4G enhances the helicase activity of 
eIF4A (9, 136, 137). Two accessory proteins, eIF4B and eIF4H, have also been 

















1.5 EUKARYOTIC INITIATION FACTOR 4E BINDING PROTEIN 1 
Sonenberg et al. discovered a set of three small binding proteins, called eIF4E(4E)-BPs 
(4E-BP1, 4E-BP2, and 4E-BP3), that inhibit cap-dependent translation by interacting 
with the mRNA 5’-cap-binding eukaryotic initiation factor eIF4E (7, 99, 104). 4E-BP1 
and 4E-BP2 are functionally redundant in terms of their impact on translation initiation 
and are regulated in a similar manner (100, 140, 141). However, very little is known 
about 4E-BP3 (142), and most studies have focused on 4E-BP1 and a few on 4E-BP2 
(140, 141, 143).  
1.5.1 Expression 
mRNA expression of 4E-BP1 and 4E-BP2 is ubiquitous in mammals, but their 
expression level appears to vary across different tissues (144). For instance, 4E-BP1 is 
found to be highly expressed in the pancreas, skeletal muscle, and white adipose 
tissue, while 4E-BP2 is predominantly expressed in the central nervous system (2, 145, 
146). Some transcription factors have been identified to regulate 4E-BP1 gene 
expression in human cells. Transcription factors ATF4 and SMAD4 upregulate 4E-BP1 
transcription to protect pancreatic cells from endoplasmic reticulum stress and inhibit 
cell proliferation, respectively (145, 147). In prostate cancer cells, the transcription factor 
c-Myc induces 4E-BP1 mRNA expression upon treatment with the mTOR inhibitor 
rapamycin (148). The one transcription factor that has been identified to downregulate 
4E-BP1 transcription is the p38/MAPK- and PI3K-dependent transcription factor EGR1, 
which promotes cell proliferation in hematopoietic stem cells (149, 150). 
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1.5.2 Regulation of 4E-BP1 Translation Inhibition  
The best characterized eIF4E binding protein is 4E-BP1, and it has a molecular weight 
of 15 kDa (151). 4E-BP1 competes with eIF4G for eIF4E binding, preventing the 
recruitment of the translation initiation machinery to the 5’ UTR of mRNA (152). The 
interaction between 4E-BP1 and eIF4E thus inhibits cap-dependent protein synthesis. 
However, this interaction is reversible, and it is regulated through phosphorylation 
mediated canonically by the mammalian target of rapamycin (mTOR) kinase in 
response to metabolic and growth-related signaling (Figure 5) (153).  
 
 
Figure 5. Schematic of the PI3K-AKT-mTOR Pathway 
The PI3K-AKT pathway activates the mTORC/Raptor (mTORC1) kinase complex that 
phosphorylates and activates S6K and phosphorylates and inhibits 4E-BP1, which 
prevents 4E-BP1 from binding eIF4E and inhibiting cap-dependent translation initiation.  
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The phosphatidylinositol-3 kinase (PI3K)-AKT pathway regulates the repressor 
function of 4E-BP1 by activating the mammalian target of rapamycin (mTOR) kinase 
(Figure 5) (154-158). The mTOR kinase forms two complexes, mTORC1 and 
mTORC2, in association with adaptor proteins Raptor and Rictor, respectively, which 
aid in substrate recognition (159-162). Activated mTORC1 phosphorylates 4E-BP1 at 
various serine and threonine residues and releases eIF4E from sequestration (163).  
 
 
Figure 6. Architecture of Human 4E-Binding Proteins 1, 2, and 3 
The eIF4E-binding site (blue) and the Raptor binding TOS motif (purple) are conserved 
in all human 4E-BPs. The Raptor binding regulatory RAIP motif is absent in 4E-BP3. 
Threonine (T) and serine (S) residues identified on these proteins are indicated in red, 
where T37, T46, S65, and T70 are shared across all human 4E-BPs (Reprinted and 
adapted by permission from Macmillan Publishers Ltd: Oncogene 32(6):671-677, 2013, 
Martineau et al. (144)). 
 
 
4E-BP1 has two short mTORC1 binding motifs, the C-terminal mTOR signaling 
(TOS) motif and the N-terminal RAIP motif, which regulate Raptor association (Figure 
6) (164-169). All 4E-BPs—1, 2, and 3—share the TOS motif that serves as a docking 
site for the mTOR adaptor protein Raptor and is also present in another mTORC1 
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substrate, the ribosomal protein S6 kinase S6K1 (Figure 5) (100, 169). Raptor 
interaction with the TOS motif allows the mTOR kinase to phosphorylate 4E-BP1 at 
residues T37, T46, S65, and T70 (153, 163, 165). 4E-BP1 and 4E-BP2 contain an N-
terminal RAIP motif, which is also important for Raptor interaction and is absent in 4E-
BP3 (164, 166, 167). Intact mTORC1 binding motifs are crucial for 4E-BP1 
phosphorylation and cap-dependent translation activation. Alanine substitutions of the 
TOS and RAIP motifs (F114A and I15A, respectively) abrogate mTORC1 binding and 




Figure 7. Sequential Phosphorylation of 4E-BP1 by mTORC1 
Priming phosphorylation of 4E-BP1 at residues T37 and T46 by mTORC1 allows for 
sequential phosphorylation at S65 and T70 (153), which leads to its dissociation from 
eIF4E and cap-dependent translation activation (Reprinted and adapted by permission 
from American Society for Clinical Investigation: J Clin Invest 121(9):3623-3634, 2011, 
Shuda et al. (170)). 
 
 
Furthermore, human 4E-BP1 interacts with eIF4E through two binding motifs. 4E-
BP1 binds eIF4E mainly through the canonical binding site 54YDRKFLM60, located 
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between mTOR-targeted phosphorylation sites T46 and S65, which contacts the dorsal 
surface of eIF4E (122, 171). 4E-BP1 shares this binding site with eIF4G—the 
conserved eIF4E-binding motif YXXXXLΦ (100). Mutation of key residues Y54 and L59 
to alanines abolish 4E-BP1 binding to eIF4E (165). Recent studies have reported that 
4E-BP1 also interacts with the lateral surface of eIF4E through the secondary binding 
site 79PGVTS83 (106), which confers to 4E-BP1 a competitive advantage over eIF4G 
and contributes to its translation inhibitory function (105). Priming phosphorylation at 
4E-BP1 T37 and T46 near the canonical binding site (Figure 8) allows for subsequent 
phosphorylation at T70 and S65 (Figure 7) (153). Sequential phosphorylation of 4E-
BP1 at these four residues decreases its affinity for eIF4E and allows eIF4G docking to 
eIF4E to bring the translational machinery to the mRNA (172, 173). Double alanine 
substitutions of critical T37 and T46 phosphorylation sites of 4E-BP1 inhibit its 
hyperphosphorylation, rendering a constitutively active 4E-BP1 that strongly binds 
eIF4E and is insensitive to mTOR inhibition (156, 174).  
Three additional 4E-BP1 phosphorylation sites have also been identified—S83, 
S101, and S112—whose regulation mechanism has remained unknown, except for that 
of the first one in recent years (Figure 6) (154, 175, 176). S83 is phosphorylated during 
mitosis by the CDK1 kinase and is located in the non-canonical binding motif that 
interacts with eIF4E (Figure 8) (177). Whether phosphorylation of this residue affects 




Figure 8. Relative Position of Phosphorylation Sites on eIF4E-Bound 4E-BP1 
(Modified from Igreja et al. 2014 (107)). 
 
1.5.3 Signaling Pathways 
4E-BP1 phosphorylation is affected by various signaling pathways that converge on 
mTORC1, such as metabolic signaling, stress conditions, and growth factors and 
cytokines (178-180). Regulation of 4E-BP1 activity through various stimuli allows the 
cell to regulate protein synthesis as needed. 
 
Metabolic Signaling 
Metabolic inputs, such as ATP, oxygen, amino acids, glucose, and lipids, regulate 4E-
BP1 phosphorylation and mRNA translation through mTORC1 modulation (Figure 9). 
Protein synthesis is an energy-intensive process, and for that reason, cells need to 
regulate their energy expenditure when ATP levels are low (181-183). The 5’-AMP-
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regulated kinase AMPK, detect the ratios of cellular AMP:ATP and ADP:ATP (184). 
When ATP levels are low, AMPK inhibits mTORC1 by phosphorylating the adaptor 
protein Raptor and activating the tuberous sclerosis proteins 1 and 2 (TSC1/2), which 
inhibit mTORC1 indirectly by stimulating the GTPase activity of the Ras homolog 
enriched in brain protein (Rheb) (185, 186). When ATP levels are restored, mTORC1 is 
activated and increases ATP production by increasing mitochondrial biogenesis in a 
positive feedback loop (187).  
Amino acid, glucose, and lipid signaling also regulates 4E-BP1 phosphorylation 
through mTORC1 (Figure 9). Amino acids are essential for protein synthesis and cell 
proliferation (188). The presence of amino acids inside lysosomes activates the GTP-
binding protein Rheb on the lysosomal membrane, and in turn, recruits and activates 
mTORC1 through Raptor interaction (189-191). Similar to amino acid signaling, glucose 
recruits mTORC1 to the lysosomal membrane through Rag GTPases that allow for 
mTORC1 to interact with the GTP-bound Rheb (192). Furthermore, lipid signaling via 
phosphatidic acids (PAs) stabilizes the assembly and activity of the mTOR-Raptor 
(mTORC1) and mTOR-Rictor (mTORC2) complexes (162, 193). All these metabolic 
pathways converge by increasing 4E-BP1 phosphorylation through mTORC1 activation, 
thus coupling increased protein synthesis to increased nutrient availability. 
 
Stress Conditions 
Certain stress conditions, such as hypoxia, genotoxicity, and apoptosis, lead to 
mTORC1 inactivation and result in decreased 4E-BP1 phosphorylation and inhibited 
cap-dependent mRNA translation (Figure 9) (178). Low levels of oxygen—hypoxia—
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leads to mTORC1 inactivation by decreasing cellular ATP levels and consequently 
activating AMPK (194-199). Low oxygen also stimulates transcription of the stress and 
hypoxia inducible gene REDD1, another negative regulator of mTORC1 that activates 
TSC2 and prevents association of Rheb with mTORC1 (195, 198, 199). Genotoxic 
stress activates the DNA-damage responsive transcription factor p53 and contributes to 
AMPK activation and increased phosphatase and tensin homolog (PTEN) expression, 
which negatively regulates the PI3K-AKT signaling pathway (200, 201). p53 activation 
leads to dephosphorylation and truncation of 4E-BP1, which cannot be phosphorylated 
and binds eIF4E with higher affinity than the full-length protein (202, 203). Furthermore, 
apoptosis signaling also blocks translation initiation through 4E-BP1 dephosphorylation 
by mTORC1 inhibition and caspase-cleavage of the N-terminal RAIP motif of 4E-BP1 
(204, 205). As in conditions of p53 activation, the truncated 4E-BP1 protein cannot be 
phosphorylated effectively and becomes a dominant inhibitor of mRNA translation. 
Unlike metabolic signaling, these stress conditions shut off cap-dependent translation 
by decreasing 4E-BP1 phosphorylation. 
 
Growth Factors and Cytokines 
Extracellular signaling through growth factors and cytokines promotes mTORC1 activity. 
Insulin promotes cell proliferation by stimulating growth factor receptors on the cell 
surface that activate downstream intracellular signaling pathways, including the PI3K-
AKT-mTOR pathway, which leads to increased 4E-BP1 phosphorylation and protein 
synthesis (104, 175). Pro-inflammatory cytokines TNFα and IκB kinase-β (IKKβ) also 
induce 4E-BP1 phosphorylation by interacting with and inactivating the mTORC1 
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inhibitor TSC2 (206). These observations have suggested that other intracellular 
pathways may target 4E-BP1 through kinases other than mTORC1. 
 
Non-Canonical 4E-BP1 Kinases 
In recent years various groups have identified kinases, other than mTORC1, that 
phosphorylate 4E-BP1: CDK1 (177, 207-209), PLK1 (210), Pim 2 (211), GSK3-β (212, 
213), p38MAPK (212, 213), ERK1/2 (155, 214), LRRK2 (215, 216), ATM (217), and 
CK1ε (218). The mitotic cyclin-dependent kinase 1 (CDK1) phosphorylates 4E-BP1 at 
T70 only in mitotic cells (207, 208). CDK1 can also phosphorylate mTOR-targeted 
residues T37, T46, and S65, and also the novel S83, which is not regulated by mTOR 
(177, 209). Another mitotic kinase, polo-like kinase 1 (PLK1), is able to phosphorylate 
4E-BP1 in vitro, but the exact phosphorylation sites have not been determined (210). 
The Pim 1/2/3 kinases have been shown to be active in cells resistant to mTOR inhibitor 
rapamycin treatment (212, 213), and Pim 2, specifically, phosphorylates 4E-BP1 at S65 
(211). Furthermore, the glycogen synthase kinase 3 β (GSK3-β) phosphorylates 4E-
BP1 at its priming sites T37 and T46 and promotes cap-dependent protein synthesis 
and cell proliferation (219). In response to UV irradiation, apoptosis, and viral infection, 
the mitogen-activated protein kinase p38 (p38MAPK) phosphorylates mouse 4E-BP1 at 
T36, T45, S64, and T69 (220-222). Related to the p38MAPK kinase, the ERK1/2 
kinases also phosphorylate 4E-BP1 at S65 and increase mTORC1 activity by inhibiting 
the mTORC1-suppressing TSC1/2 proteins (155, 214). Furthermore, the leucine-rich 
repeat kinase 2 (LRRK2) phosphorylates 4E-BP1 at the T37 and T46 sites (215, 216). 
Interestingly, a couple of enzymes that phosphorylate at non-mTORC1-regulated sites 
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have also been identified. First, the ataxia-telangiectasia mutated kinase (ATM) is 
normally activated by ionizing radiation and double-stranded DNA breaks and also 
phosphorylates 4E-BP1 at S112 following insulin stimulation (217). Second, the casein 
kinase 1ε (CK1ε) phosphorylates 4E-BP1 at T41 and T50 in breast cancer cells and 
appears to promote mRNA translation (218). The existence of other 4E-BP1 kinases 
could explain mTOR inhibitor resistance in cancer cells of various tumor types (223-
225), and it also suggests that several signaling pathways converge on 4E-BP1 and 











Figure 9. Signaling Pathways Targeting the mTORC1-4E-BP1 Axis 
mTORC1 kinase activity inhibits 4E-BP1 by phosphorylation, thereby activating cap-
dependent mRNA translation. Multiple upstream regulators, such as growth factors, 
nutrients, and stress, stimulate mTORC1 and regulate protein synthesis and cell 
proliferation via 4E-BP1 (Reprinted and adapted by permission from Macmillan 













1.5.4 Cell Cycle Progression 
The PI3K-AKT-mTORC1 pathway is well known to regulate both cell growth and cell 
cycle progression, which are necessary for cell proliferation (226). mTORC1 inhibition 
by rapamycin blocks cell cycle progression and preferentially arrests cells transiting 
through the G1 phase (160, 227). Furthermore, raptor knockdown and serum starvation 
impair G1/S progression by inhibiting mTORC1 activity (228, 229). Some reports 
indicate that mTORC1 exerts its influence on cell cycle progression by modulating the 
activity of cyclin-dependent kinases, the gatekeepers of the cell cycle (230, 231). Cells 
from dTOR (Drosophila target of rapamycin)-null fruit flies express lower levels of cyclin 
E than the wild type cells and, as a result, are arrested in the G1/S transition (231). 
Downstream of mTORC1, 4E-BP1 hyperphosphorylation has been linked to an increase 
in CDK1 and CDK2 and cyclin E, D1, and B1 protein levels, which can be reversed by 
mTOR inhibition (230). Furthermore, overexpression of a non-phosphorylatable 4E-BP1 
mutant also leads to G1/S phase arrest, decreased cell size, and thus decreased cell 
proliferation (174, 232). Conversely, eIF4E overexpression and increased S6K1 activity 
contributes to S phase progression and increased cell size (10, 141, 233, 234). These 
observations indicate the mTORC1, through 4E-BP1 targeting, is regulating not only cell 
growth but also cell cycle progression. Translation inhibition by 4E-BP1 of mRNAs 
encoding pro-proliferative genes, such as c-Myc, ODC, VEGF, cyclins, and CDKs, could 





Translation During Mitosis 
Global mRNA translation has long been assumed to be inhibited during mitosis. Several 
studies have shown that protein synthesis is decreased in HeLa cells (235, 236) and 
Chinese hamster ovary (CHO) cells (237) that were arrested in mitosis by treatment 
with nocodazole, a drug that destabilizes microtubules. One report shows that 4E-BP1 
is dephosphorylated in nocodazole-arrested mitosis cells and provides additional 
evidence that translation is suppressed (236). Interestingly, IRES-containing poliovirus 
mRNA translation was unaffected in mitosis-arrested HeLa cells (238, 239), and 
mTORC1 activity was preserved during mitosis (229). These findings indicated that a 
subset of the global mRNA population, transcripts containing IRES structures in their 5’ 
UTR, can escape the global translational suppression during mitosis. To determine 
whether cellular mRNAs containing IRES structures could escape the observed 
translational suppression, subsequent studies examined the translation of the ornithine 
decarboxylase enzyme (ODC), important for polyamine biosynthesis (30). ODC 
expression is translationally regulated in a cell cycle-dependent manner, peaking at the 
G1/S transition and at the G2/M transition (240). Like the poliovirus transcripts, ODC 
mRNA translation is not suppressed during mitosis and does not depend on eIF4E (30). 
The p53-activated tumor suppressor protein 14-3-3σ has been reported to enhance the 
cap-independent translation of the IRES-containing p58 PITSLRE and p27 Kip1 
transcripts during mitosis by targeting the translation initiation factors eIF4B and eIF2 
(241). One of the eIF4F complex members crucial for cap-dependent translation, eIF4G, 
is phosphorylated at Ser1232 by CDK1 during mitosis, which prevents its association 
with eIF4A and may also explain the observed translational suppression (242). 
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In recent years, the idea that cap-dependent mRNA translation is suppressed 
during mitosis has been challenged by various groups and work presented in the 
following chapters (177, 209, 243, 244). Emerging ribosomal profiling studies (79, 80, 
244) and sensitive single-cell metabolic labeling assays (209) have shown that mitotic 
mRNA translation is predominantly cap-dependent. In line with these observations, 
multiple studies have shown that 4E-BP1 is in fact hyperphosphorylated and inactivated 
during mitosis (177, 207-209, 243). The discrepancy between previous and recent 
studies has been attributed to the cell cycle synchronization method employed to arrest 
cells in mitosis. Previous studies utilized microtubule-destabilizing drugs, such as 
nocodazole, which has been reported to inhibit global mRNA translation (243). This 
would explain why only IRES-containing transcripts were able to be translated in the 
mitotic cell population. On the other hand, recent studies have resorted to mild 
synchronization methods to enrich mitotic cells, such as manual mitotic shake-off, S-
phase arrest and release by double-thymidine block, and G2/M arrest and release by 






1.6 TRANSLATION IN CANCER 
Dysregulation of cap-dependent mRNA translation has been recognized to play an 
important role in cancer cell proliferation and survival (159). The signaling pathway 
responsible for activating protein synthesis, the PI3K-AKT-mTOR, is often overactivated 
in tumorigenesis, and has indicated that cap-dependent mRNA translation is increased 
in cancer cells, resulting in the overproduction of proteins that support cell proliferation 
and protect from cell death (246). This kind of dysregulation is attributed to the 
modulation of translation initiation effectors eIF4E and 4E-BP1 in favor of increased 
mRNA translation (143). Over the last couple of decades, the level of expression and 
phosphorylation of the cap-binding protein eIF4E and translation inhibitor 4E-BP1 have 
been identified as useful prognostics for multiple cancers (247-249). Interestingly, some 
tumor viruses, particularly the Merkel cell polyomavirus, have been shown to target 4E-
BP1 to activate mRNA translation (170, 250-253), which highlights the importance of 








1.6.1 eIF4E Overexpression 
Due to its importance for cap-dependent mRNA translation of genes necessary for cell 
proliferation, eIF4E has been shown to act as a proto-oncogene (234, 254). eIF4E 
overexpression and upregulation lead to malignant transformation of rodent fibroblasts 
induced by other oncogenes, such as E1A, v-myc, and Ras (233, 234, 255-257). 
Knockdown of eIF4E reverses the tumorigenic phenotype of these transformed cells 
(258, 259). eIF4E is also overexpressed in various human cancers (260) and is 
regulated transcriptionally by c-Myc (261) and post-translationally by trans-acting 
translation initiation protein factors (262), ubiquitin-mediated protein degradation (263), 
and MNK1/2-mediated phosphorylation (123).  
Mitogen-activated protein kinases (MAPK)-interacting protein kinases MNK1 and 
MNK2 bind eIF4G and phosphorylate human eIF4E at S209 (123, 146, 264, 265). The 
function of this phosphorylation is not yet clear, as it has not yet been determined 
whether it affects the affinity of eIF4E for the 5’ cap or translation initiation. MNK1/2 
double knockout in lymphoma and glioma mouse models does not exhibit any effects on 
cell growth when eIF4E S209 is not phosphorylated, but it appears to prevent cells from 
undergoing transformation (146). In line with this observation, phospho-defective eIF4E 
S209A knock-in mouse cells are resistant to transformation (266). The MNK1/2 kinases 
are able to phosphorylate eIF4E by binding to the C-terminus of eIF4G, which is bound 
to eIF4E when the eIF4F translation initiation complex has assembled on the 5’ cap 
(123, 267). These observations suggest that eIF4E S209 phosphorylation may enhance 
cap-dependent translation in tumorigenesis, which may be disrupted upon 4E-BP1 
displacing eIF4G and, in turn, preventing MNK1/2 from phosphorylating eIF4E. 
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1.6.2 4E-BP1 Hyperphosphorylation 
Multiple signaling pathways that are dysregulated in cancer, such as the PI3K-AKT-
mTOR and RAS-MAPK pathways, have been found to inactivate 4E-BP1 by 
phosphorylation. Increased protein synthesis through eIF4F-mediated translation leads 
to increased cell growth and proliferation. Thus, 4E-BP1 is a critical contributor to cell 
transformation, which has been shown to be dependent on sufficient eIF4F activity 
(268). In particular, eIF4F promotes cap-dependent translation of mRNAs encoding 
proteins that play a vital role in cell survival, proliferation, and migration (262). 
The PI3K-AKT-mTOR pathway is commonly dysregulated in cancers and leads 
to increased 4E-BP1 phosphorylation and enhanced cap-dependent translation (141). 
Interestingly, phosphorylated 4E-BP1 protein levels are augmented in tumors in 
response to this signaling (248). Moreover, expression of a non-phosphorylatable 4E-
BP1 antagonizes the tumorigenic phenotype of cancer cells in which the PI3K-AKT-
mTOR pathway is constitutively activated (269). Double knockout of 4E-BP1 and 4E-
BP2 in mouse embryonic fibroblasts leads to increased cell proliferation and renders the 
cells insensitive to mTOR inhibitor treatment (223). By phosphorylating 4E-BP1, the 
PI3K-AKT-mTOR frees its ultimate target eIF4E and allows it to recruit the rest of the 
translation initiation machinery to synthesize pro-proliferative proteins.  
Another pathway that is activated in cancer is the RAS-MAPK pathway, which 
activates the MNK1/2 kinases that phosphorylate eIF4E at S209 (223, 264, 265). 
MNK1/2 can only phosphorylate eIF4E when eIF4G is bound to it (123). Expression of a 
non-phosphorylatable 4E-BP1 mutant in non-small cell lung cancer cells inhibits eIF4E 
phosphorylation by displacing eIF4G and preventing the recruitment of MNK1/2 (270). 
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RAS-MAPK signaling also appears to induce 4E-BP1 phosphorylation independently of 
PI3K-AKT signaling (223, 271). In tumor cells in which the two pathways are activated, 
4E-BP1 phosphorylation is only abrogated when both pathways are inhibited (223). 
Notably, colon cancer cells become insensitive to RAS-MAPK and PI3K-AKT signaling 
when eIF4E is overexpressed or 4E-BP1 is knocked down (223). These findings 
suggest that the PI3K-AKT-mTOR and RAS-MAPK signaling pathways work together to 
activate both 4E-BP1 and eIF4E phosphorylation. 
Finally, the tumor suppressor p53, which induces cell cycle arrest, DNA repair, 
senescence, and apoptosis, downregulates protein synthesis by inhibiting mTORC1 
activity, which leads to 4E-BP1 dephosphorylation and truncation and thus increases 
the interaction between 4E-BP1 and eIF4E (200, 204, 205). The p53 gene is often 
mutated in various cancers, and some studies performed in cells with a p53 defect show 
that the acquisition of a tumorigenic phenotype is attributed to eIF4E overexpression or 
loss of 4E-BP1/2 expression and activity (214, 272). These results suggest that 
mutations that inhibit the tumor suppressor function of p53 allow for the phosphorylation 
and inactivation of 4E-BP1 through a dysregulated PI3K-AKT-mTOR pathway. 
1.6.3 Tumor Viruses  
Some cancer-causing viruses—HPV, HCV, KSHV, and MCV—are known to target the 
cap-dependent translation initiation machinery to promote the synthesis of their own 
proteins (273). The cervical cancer-causing human papilloma virus (HPV) encodes two 
major oncoproteins E6 and E7 (274). Essential for HPV replication and transformation, 
HPV E7 mRNA translation is activated by mTOR-mediated phosphorylation and 
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inactivation of the translation inhibitor 4E-BP1 (251). Furthermore, E6 upregulates the 
transcription of the 5’ cap-binding protein eIF4E, which contributes to its tumorigenic 
activity (250). The hepatitis C virus (HCV), which causes hepatocellular carcinoma, 
encodes the nonstructural protein 5A (NS5A) that activates the mTORC1 kinase and 
induces 4E-BP1 phosphorylation and inactivation (253).  
The two most recently discovered tumor viruses, KSHV and MCV, cause cancers 
associated with immunosuppression and also target cap-dependent mRNA translation 
initiation. The Kaposi sarcoma-associated herpesvirus (KSHV) causes Kaposi sarcoma 
(275) and activates mRNA translation by inducing 4E-BP1 phosphorylation (252), which 
leads to the synthesis of paracrine signaling proteins that are essential for tumor growth, 
namely VEGF-A and interleukin 6 (IL-6) (276). The Merkel cell polyomavirus (MCV) 
(277), which causes most Merkel cell carcinomas, encodes a small T antigen (sT) 
oncoprotein that also induces 4E-BP1 phosphorylation and activates cap-dependent 
translation (170, 209). Cap-dependent mRNA translation activation, thus, appears to be 
a critical target for the synthesis of tumor virus proteins and their transforming activities. 
1.6.4 Merkel Cell Polyomavirus 
Hundreds of thousands of viruses have been discovered, but only seven viruses are 
known to cause human cancers (278). Identifying a novel virus that causes a human 
cancer provides a new model to understand tumorigenesis. Nearly a decade ago, a 
novel cancer virus was discovered in Merkel cell carcinoma. Merkel cell carcinoma 
(MCC) is a very rare and aggressive skin cancer with a mortality rate of ~30% and an 
incidence of at least 1,500 cases per year in the United States, which has tripled in the 
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last two decades (279-281). MCC appears to arise from transformed Merkel cells, which 
are mechanoreceptor cells found in the basal layer of the epidermis (282). It is more 
prevalent in the elderly population, and risk factors for MCC occurrence include UV 
exposure and immunosuppression, particularly due to organ transplantation and the 
acquired immunodeficiency syndrome (AIDS) (283-285).  
Due to its association with immunosuppression, the origin of MCC was 
suspected to be infectious. In 2008 a bioinformatics technique called digital 
transcriptome subtraction (DTS) was developed to search for viral sequences in cDNA 
libraries generated from MCC tumors (277). After transcripts that corresponded to 
human sequences were subtracted, databases containing only sequences of infectious 
origin remained. A non-human sequence that was highly homologous to the African 
green monkey lymphotrophic polyomavirus was identified (277). Rapid amplification of 
cDNA ends (3’-RACE) revealed that a polyomavirus genome, eventually termed Merkel 
cell polyomavirus (MCV), was clonally integrated into the genome of 80% of the MCC 
tumors tested (277). Studies performed four years later with enhanced detection 
methods showed that 97% of MCCs are associated with this virus, suggesting that 
possibly all MCCs are caused by MCV (286). 
Animal polyomavirus research has been central in cancer research. The first two 
polyomaviruses that were identified—the simian virus 40 (SV40) and the mouse 
polyomavirus (MPyV)—transform cells and can cause cancer in animals. Research on 
the SV40 large T antigen revealed the importance of two host cell tumor suppressor 
proteins, p53 and Rb (287). Studies on the SV40 small T antigen found the tumor 
suppressor function of the protein phosphatase PP2A, which is a negative regulator of 
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the AKT-mTOR pathway (288). Furthermore, mouse polyomavirus research on its 
middle T antigen revealed the critical role of the proto-oncogenic PI3K signaling 
pathway, which also targets the AKT-mTOR pathway (289). However, these viruses are 
not oncogenic in humans (290). Various polyomaviruses besides MCV have been 
identified in humans besides MCV. Although these viruses have a high seroprevalence 
in various human populations, they are not implicated in cancer (291-294), expect for 
the BK virus that is associated with some genitourinary tumors in transplant patients 
(295). MCV is the first and only polyomavirus known to cause human cancer and has 
become a novel model to understand how cancers arise.  
 
Genome  
MCV, like other polyomaviruses, possesses a characteristic circular double-stranded 
DNA genome (approximately 5.4 kb) with an early region encoding two major 
overlapping tumor (T) antigens, small T (sT) and large T (LT), and a late region 
encoding three capsid proteins, VP1, VP2, and VP3 (Figure 10) (284). The tumor 
antigens LT and sT are the major oncoproteins encoded by MCV and are expressed in 
MCC tumors. Expression of these T antigens is required for MCC tumor cell growth, 
proliferation, and survival (296, 297). In addition to the major LT and sT, the early region 
also encodes the understudied 57kT antigen and the alternate frame of the LT ORF 
protein (ALTO) (298). Early and late coding regions are a common feature of DNA 
viruses and provide temporal regulation for viral gene expression. Polyomavirus tumor 
antigen genes are expressed upon viral entry to start viral DNA replication, after which 
the late viral capsid genes are expressed to produce new virions (299). MCV genome 
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has a non-coding regulatory region (NCRR) that separates the early and late genes and 
contains the viral origin of replication (Ori) and bidirectional transcription promoters for 
the two regions (300). In addition to these genes, MCV encodes a 22-nt microRNA, 
named MCPyV-miR-M1-5p, that has been identified in 50% of MCV-positive MCCs and 
may play a role in viral replication regulation and immune invasion (301, 302). 
 
 
Figure 10. Wild-Type Merkel Cell Polyomavirus Genome  
The wild-type Merkel cell polyomavirus genome is 5,387 bp long and contains early and 
late coding regions separated by the noncoding regulatory region (NCRR) that has an 
origin of replication (red) and promoters for bidirectional transcription. The early region 
encodes the early proteins large T antigen (LT), small T antigen (sT), and 57-kT 
antigen. The late region encodes the capsid viral protein genes 1, 2, and 3 (VP1, VP2, 







Capsid Proteins  
The MCV late region encodes the major capsid proteins VP1 and VP2 (Figure 10) 
(303). Expression of VP1 alone is sufficient for virus-like particle (VLP) production, 
which are ~40-55 nm in size, but assembly of both VP1 and VP2 is necessary for in 
vitro infection (304-306). Unlike the VP1 and VP2 genes, the VP3 gene is not expressed 
in MCV infection (304, 307). While the cell surface receptor for other polyomaviruses 
has been determined to be the ganglioside Gt1b sialic acids (308, 309), MCV 
pseudovirions rely on heparan sulfate, a sulfated glycosaminoglycan, for viral entry 
(306). Structural studies on VP1 protein complexes indicate that MCV uses primarily 
glycosaminoglycans for attachment and a sialylated glycan for internalization, which 
suggests a two-step entry process that is different from other polyomaviruses (310). 
 
Large Tumor Antigen  
The proteins encoded by DNA virus early genes target host cell cycle regulators and 
tumor suppressors in order to promote viral DNA replication (287, 288, 311, 312). The 
full-length MCV large T antigen (LT) is a large protein consisting of 817 amino acids and 
has various domains whose functions are important for MCV replication (Figure 11) 
(313). The DnaJ and CR1 domains in the N-terminus of LT bind the transcription 
inactivating chaperone protein Hsc70 (314, 315). This interaction between LT and 
Hsc70 has been shown to be permissive for MCV replication in vitro (316). Additionally, 
the LT antigen has a nuclear localization signal (NLS) and a conserved Rb-binding motif 
(LXCXE) between amino acids 100-300—a region different from other polyomaviruses 
and unique to MCV (317). Termed the MCV T antigen unique region (MUR), this stretch 
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of amino acids has been shown to interact with the vacuolar sorting protein Vam6p, 
which leads to nuclear translocation of this protein and lysosomal clustering (318). 
Expression of a Vam6p binding mutant LT enhances viral replication, while 
overexpression of human Vam6p inhibits this process (300). These findings suggest 
that the interaction between LT and Vam6p may help establish latency in the host cell. 
 
 
Figure 11. MCV Large T and Small T Antigen Domain Architecture 
The full-length MCV LT schematic shows the location of its different domains, 
particularly its Rb-binding and origin-binding (OBD) domains. The MCV sT shares the 
DnaJ binding domain with LT and possesses a PP2A binding site (Modified from Chang 
and Moore 2012 (284)). 
 
 
As in other polyomavirus T antigens, the conserved LXCXE motif allows MCV LT 
to bind the tumor suppressor retinoblastoma protein Rb (315, 319). This interaction is 
important to drive the cells into S phase by upregulating the transcription of E2F target 
genes, particularly cyclin-dependent kinases, cyclins, checkpoint regulators, and DNA 
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repair and replication proteins (317, 320, 321). An intact LXCXE is critical for MCC cell 
growth, as expression of an Rb-binding mutant LT in MCV LT-knockdown MCC cells 
cannot rescue their growth (322). Furthermore, expression of a LT protein with an intact 
LXCXE motif upregulates the expression of anti-apoptotic protein survivin, whose 
pharmacological inhibition in MCC xenograft mice increases their survival (321, 323). 
The regions necessary for viral replication are found in the MCV LT C-terminal 
half (Figure 11). The origin binding domain (OBD) recognizes and binds the 71-bp 
origin of replication located in the NCRR (324). Two phosphorylation sites, T297 and 
T299, regulate the ability of LT to start DNA replication in opposite ways (325). 
Phosphorylation of T297 inhibits LT interaction with the origin of replication. On the 
other hand, phosphorylation of T299 is necessary for LT to initiate replication. Also on 
the C-terminal half of LT resides a helicase domain, between amino acids 441-817, that 
is required for LT oligomerization and replication initiation at the origin in the NCRR 
(320). Interestingly, the LT C-terminus is found to be truncated in MCC tumors, which 
eliminates the replication function of LT (315, 326). Recent findings have shed light on 
the anti-proliferative potential of the MCV LT C-terminus and may provide an additional 
explanation for its truncation in tumors. The helicase domain of LT is reportedly capable 
of inducing the host DNA-damage response (327). Phosphorylation of S816 in this 
domain by DNA-damage response ATM kinase induces apoptosis (328). Furthermore, 
the growth of MCC cells and SV40-immortalized human fibroblasts is suppressed by the 




Small Tumor Antigen  
The MCV small T antigen (sT) is the second major protein encoded by the MCV early 
region, and it shares the first 78 amino acids of the LT N-terminus and has a length of 
186 amino acids (Figure 11) (313). Unlike LT in MCC, MCV sT is unaffected by tumor 
mutations, and its coding region is found intact (315). In the SV40 model of 
transformation, LT is the primary oncoprotein (290), whereas MCV-driven tumorigenesis 
relies mainly on sT, whose expression alone is sufficient to transform rodent fibroblasts 
(170) and induces tumor formation in transgenic mouse models (330, 331). 
The C-terminus of MCV sT possesses a protein phosphatase 2A binding site that 
is conserved across polyomavirus sT antigens (288). For instance, the SV40 sT 
interacts with PP2A and inhibits the dephosphorylation of AKT, constitutively activating 
its downstream targets (332-334). While MCV sT can bind PP2A subunits and PP4C 
(335, 336), its transformation activity is independent of this interaction (170). Expression 
of this viral protein has modest effects on AKT-activating S473 phosphorylation but no 
effect on mTOR expression (170). On the other hand, the interaction of MCV sT and 
PP4C has been shown to inhibit the nuclear translocation of NF-κB essential modulator 
(NEMO), which consequently blocks host inflammatory signaling (335). Another 
reported consequence of this interaction is facilitating cell migration by destabilizing 
microtubules through targeting of the cytoskeletal regulator stathmin (337).  
MCV sT also promotes viral replication by stabilizing the LT protein (300, 316). 
sT inhibits the E3 ubiquitin ligase SCF Fbw7, which targets LT for proteasomal 
degradation and thus inhibits MCV replication (338). In addition, sT also stabilizes other 
Fbw7 substrates, cyclin E and c-Myc, that are contributors to cell transformation (338). 
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The LT stabilizing domain (LSD), mapped between amino acids 91-95, is important not 
only for MCV sT binding and inactivating of Fbw7, but also for its transformation activity 
(330, 338). MCV sT has also been shown to coordinate iron/sulfur clusters through two 
CXCXXC cysteine motifs, which are required for LT-mediated viral replication (339). 
Furthermore, MCV sT targets host cap-dependent translation by inducing the 
hyperphosphorylation-inactivation of cap-dependent translation inhibitor 4E-BP1 in an 
mTOR-independent manner (170). It is speculated that the known consequences of 4E-
BP1 inactivation, such as increased eIF4E activity and cap-dependent translation, might 
be key contributors to tumorigenesis caused by MCV (170). Knockdown of MCV sT in 
MCV-positive MCC cell lines decreases translation initiation complex assembly at the 7-
methyl-guanine cap (170). Moreover, expression of a constitutively active, non-
phosphorylatable 4E-BP1 abolishes MCV sT-induced rodent fibroblast transformation, 
indicating that 4E-BP1 inhibition is required for sT cell transformation activity (170).  
Recent studies, included in the subsequent chapters of this dissertation, have 
clarified the mechanism of MCV sT targeting of 4E-BP1. MCV sT promotes mitogenesis 
by inhibiting another E3 ubiquitin ligase, the mitotic checkpoint APC/C cdc20 (209). This 
results in the activation of the mitotic CDK1 kinase to hyperphosphorylate 4E-BP1 and 
activate cap-dependent translation (209). MCV sT induction of mitosis revealed that 
mitotic cells in general express a unique hyperphosphorylated form of 4E-BP1, that 
contains a novel phosphorylation at S83 (177). Expression of an alanine mutant of S83 
modestly reverses MCV sT-induced cell transformation (177). These findings suggest 
that mitotic cap-dependent mRNA translation activated by CDK1 phosphorylation of 4E-
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BP1 is permissive for viral-induced tumorigenesis and possibly for non-viral-induced 

























The studies presented in this dissertation focused on the regulation of cap-dependent 
mRNA translation inhibitor protein 4E-BP1 during normal mitosis and mitosis enforced 
by the MCV sT oncoprotein. Chapter 2 shows that: 1) MCV sT increases mitogenesis by 
targeting the cellular anaphase promoting complex E3 ligase; 2) MCV sT induces 
mTOR-independent 4E-BP1 hyperphosphorylation; 3) CDK1 directly phosphorylates 
4E-BP1 at T37, T46, S65, and T70 during mitosis, forming a high molecular weight δ 
phospho-species; 4) δ-4E-BP1 is induced in mitosis during normal cell cycling; and 5) 
CDK1 activates cap-dependent translation during mitosis. Chapter 3 shows that: 1) δ-
4E-BP1 hyperphosphorylation is a feature of mitosis across multiple cancer cell lines; 2) 
CDK1 phosphorylates 4E-BP1 at S83; 3) S83-phosphorylated 4E-BP1 colocalizes with 
centrosomes during mitosis and peaks at metaphase; and 4) mutation of 4E-BP1 S83 
does not affect global cap-dependent translation but partially reverses MCV sT-induced 
rodent cell transformation. Both studies provide evidence that cap-dependent mRNA 
translation is active during mitosis and reveal the role of CDK1 as a novel regulator of 







2.0  CDK1 SUBSTITUTES FOR MTOR KINASE TO ACTIVATE CAP-DEPENDENT 
PROTEIN TRANSLATION DURING MITOSIS 
Work described in this chapter was published in the Proceedings of the Academy of 
Sciences 
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This chapter describes an alternative control mechanism for maintaining cap-dependent 
translation during mitosis revealed by a viral oncoprotein, the Merkel cell polyomavirus 
small T antigen (MCV sT). We find MCV sT to be a promiscuous E3 ligase inhibitor 
targeting the anaphase promoting complex, which increases cell mitogenesis.  MCV sT 
binds through its LSD region to Cdc20 and, possibly, Cdh1 E3 ligase adapters. This 
activates cyclin-dependent kinase 1/Cyclin B1 (CDK1/CYCB1) to directly 
hyperphosphorylate 4E-BP1 at authentic sites, generating a mitosis-specific, mTOR-
inhibitor resistant δ phospho-isoform not present in G1-arrested cells.  Recombinant 4E-
BP1 inhibits capped mRNA reticulocyte translation, which is partially reversed by 
CDK1/CYCB1 phosphorylation of 4E-BP1. eIF4G binding to the eIF4E-m7GTP cap 
complex is resistant to mTOR inhibition during mitosis but sensitive during interphase. 
Flow cytometry, with and without sT, reveals an orthogonal pH3S10+ mitotic cell 
population having higher inactive p4E-BP1T37/T46+ saturation levels than pH3S10- 
interphase cells. Using a Click-iT flow cytometric assay to directly measure mitotic 
protein synthesis, we find that most new protein synthesis during mitosis is cap-
dependent, a result confirmed using the eIF4E/4G-inhibitor drug 4E1RCat. For most cell 
lines tested, cap-dependent translation levels were generally similar between mitotic 
and interphase cells and the majority of new mitotic protein synthesis was cap-
dependent. Mitosis is commonly thought to be associated with reduced cap-dependent 
protein translation. These findings suggest that mitotic cap-dependent translation is 
generally sustained during mitosis by CDK1 phosphorylation of 4E-BP1 even under 




Eukaryotic initiation factor 4E (eIF4E)-binding protein, 4E-BP1, is a principal target for 
mTORC1 (mechanistic target of rapamycin complex (159, 223, 269). mTOR regulates a 
variety of metabolic signaling pathways related to ribosomal biosynthesis and 
autophagy that contribute to cancer cell survival (159, 223, 246, 248, 340). Increasing 
evidence indicates that direct mTORC1 phosphorylation of 4E-BP1 may be the key 
event in mTOR-associated tumorigenesis (269). In the absence of activated mTOR, 
hypophosphorylated 4E-BP1 sequesters eIF4E to prevent assembly of eIF4F complex 
components onto capped mRNA, inhibiting cap-dependent translation.  When 4E-BP1 is 
phosphorylated by mTOR (156), first at critical priming threonine (T)37 and T46 
residues and then at other sites, 4E-BP1 is inactivated and releases eIF4E to allow 
initiation of cap-dependent translation (172). Other non-mTOR kinases, including cyclin-
dependent kinase 1 (CDK1), have been shown to be able to phosphorylate 4E-BP1 
(163, 207, 210, 219) but have not been extensively examined in vivo for their effects on 
4E-BP1 regulated cap-dependent translation.  
Protein synthesis has been described to decrease during mitosis relative to 
interphase in reports dating back to the 1960s (341, 342). There are two issues, 
however, with this conclusion:  1) Mitotic cells represent less than 1% of the total cell 
population in bulk culture and even under stringent conditions, high levels of interphase 
cell contamination can occur. 2) Many studies of mitotic cap-dependent translation rely 
on cell cycle synchronization studies with microtubule inhibitors, e.g., nocodazole, which 
are also mitotic translation inhibitors (243). Under these conditions, comparisons of 
interphase and mitotic translation can be imprecise.  Single-cell measurements, such as 
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flow cytometry, can potentially overcome these concerns. Additionally, a highly 
hyperphosphorylated 4E-BP1 isoform called δ-4E-BP1 is present in mitotic cells (207, 
208). This hyperphosphorylated isoform is predicted to promote rather than inhibit cap-
dependent protein translation and is therefore inconsistent with the standard model.  
Our studies on Merkel cell polyomavirus (MCV) provide insights into these 
issues. MCV is a small double-stranded DNA virus discovered in 2008 by our lab that 
causes most cases of the human skin cancer, Merkel cell carcinoma (MCC) ((277); for 
review see (284, 303, 343)). The 19-kDa MCV small T (sT) antigen is a transforming 
oncoprotein required for MCC cell growth (170, 296). A region of the sT protein 
spanning amino acid residues 91-95 called the LSD (Large T stabilization domain), 
promotes δ-4E-BP1 hyperphosphorylation (336), rodent cell transformation (338) and 
fibroblast proliferation in a mouse transgenic model (170, 330). Expression of the 
phosphorylation-defective, dominant-positive (DP)-4E-BP1 (153) with alanine 
substitution mutations at priming T37/T46 (4E-BP1T37A/T46A) reverses sT-induced rodent 
fibroblast transformation, suggesting a direct link between 4E-BP1 phosphorylation 
status and sT-induced transformation (170). Surprisingly, sT-induced δ-4E-BP1 
hyperphosphorylation is not dependent on mTOR activity (170). The sT LSD region is 
known to bind the Fbw7 E3 ligase to promote cell proliferation but Fbw7 targeting is not 
sufficient to explain either cell transformation or 4E-BP1 hyperphosphorylation (338). 
We show here that MCV sT, through its LSD domain, also promotes mitogenesis 
and 4E-BP1 hyperphosphorylation by functioning as a promiscuous E3 ligase inhibitor 
that also targets cellular anaphase-promoting complex/cyclosome (APC/C) E3 ligase 
activity. During sT-induced mitosis, sT-induced CDK1/CYCB1 rather than mTOR 
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directly phosphorylates 4E-BP1 to the mitosis-specific δ isoform. Using a flow 
cytometry-based method to directly measure mitotic cap-dependent protein synthesis 
for the first time, we do not detect a general shift from cap-dependent to cap-
independent protein translation in mitotic cells compared to interphase cells. Mitotic 
cells actually show higher saturation levels of p4E-BP1T37/T46+, consistent with 4E-BP1 
inactivation, than interphase cells. Consistent with this, and in contrast to previous 
studies, we find that δ-4E-BP1 positive mitotic cells show high levels of cap-dependent 
protein translation that is reduced by the cap translation inhibitor 4E1RCat. When 
accentuated or sustained high levels of mitotic cap-dependent protein translation may 
play a role in cancer cell transformation and contribute to mTOR-inhibitor resistance in 














2.2 MATERIALS AND METHODS 
2.2.1 Cell Culture and Transfection/Transduction 
293, 293FT, U2OS, HeLa and BJ-tert (BJ-T) cells were maintained in DMEM (Corning 
Cellgro) supplemented with 10% FBS. 293 and 293FT cells were transfected using 
Lipofectamine 2000 (Invitrogen) and harvested after 48 h.  
2.2.2 Kinase Inhibitors 
The following active-site kinase inhibitors were dissolved in DMSO and used for kinase 
inhibition and in vitro phosphorylation experiments: mTOR kinase inhibitor PP242 
(Selleckchem), CDK1 kinase inhibitor RO-3306 (Calbiochem) and pan Aurora kinase 
inhibitor VX-680 (Selleckchem). 
2.2.3 Plasmids and Transfections 
Plasmids pcDNA6.sTco (wild-type MCV sT, codon optimized) and pcDNA6.sTmLSD 
that were used for transient transfection experiments are previously described (170, 
338). To efficiently express SV40 sT, codon-optimized SV40 sT (GenBank accession 
number KM359729 (336)) was generated by overlapping PCR. 
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2.2.4 Immunoblotting and Antibodies 
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 1% Triton X-100, 
2 mM Na3VO4, 2 mM NaF and 0.1% SDS) containing protease inhibitors (Roche). 
Lysates were resolved by 12% SDS-PAGE and transferred to nitrocellulose. 
Membranes were blocked with 5% milk in 1X TBS and incubated with primary 
antibodies overnight at 4 °C. Blots were subsequently incubated with IRDye-labeled 
anti-rabbit or anti-mouse secondary antibodies and analyzed on the Odyssey infrared 
scanner (LI-COR Biosciences). The following primary antibodies were used in this 
study: total 4E-BP1, phospho-4E-BP1T37/T46, phospho-4E-BP1T70, phospho-4E-BP1S65, 
eIF4E, eIF4G, phospho-S6S242/S244, total S6, phospho-Histone H3S10, total Histone H3, 
cdc25C, phospho-Aurora A/B/C, total Aurora A, total Aurora B, Skp2, Cdc20, Plk1, 
Claspin (Cell Signaling), total Aurora C, phospho-MPM2 (Millipore), Cdh1 (Calbiochem), 
cyclin A, cyclin D1, cMyc (Santa Cruz Biotechnology), HA (Covance), FLAG (Sigma 
Aldrich), 800CW goat polyclonal anti-rabbit IgG and 680CW goat polyclonal anti-mouse 
IgG (LI-COR Biosciences). Previously described CM8E6 (338) and CM5E1 (170) were 
used to detect MCV sT. For cycloheximide (CHX) chase assays, BJ-T cells were treated 
with 100 µg/mL CHX and harvested at different time points for immunoblotting. 
2.2.5 Immunoprecipitation 
293 cells co-transfected with sT constructs and myc-cdh1, HA-cdc20 or pcDNA6 empty 
vector were harvested after 48 h and lysed in IP lysis buffer (50 mM Tris-HCl pH 7.4, 
0.15 M NaCl, 1% Triton X-100, 2 mM Na3VO4 and 2 mM NaF) supplemented with 
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protease inhibitors (Roche). Pre-cleared lysates were incubated with either anti-myc tag 
or anti-HA antibodies overnight at 4 °C. Immune complexes were precipitated with 
protein A/G sepharose beads (Santa Cruz) for 1 h at 4 °C. Beads were collected, 
washed with lysis buffer and boiled in 1X SDS loading buffer. Samples were subjected 
to SDS-PAGE and immunoblotting. 
2.2.6 Two-Dimensional Electrophoresis 
293 cells were lysed using lysis buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1% Triton 
X-100, 2 mM Na3VO4, 2 mM NaF) supplemented with protease inhibitors (Roche). 
Clarified lysates were focused using immobilized pH 3-6 gradient strips (Bio-Rad) with 
linear voltage ramping for 2 h at 200 V, 2 h at 500 V and 16 h at 800 V. Focused 
proteins were then subjected to SDS-PAGE for two-dimensional resolution and detected 
by immunoblotting.  
2.2.7 Flow Cytometry 
293 and BJ-T cells were trypsinized and fixed in 70% ethanol for DNA staining or in 
10% buffered formalin for AHA incorporation assays. Fixed cells were washed with PBS 
containing 1% FBS and permeabilized with 0.25% Triton X-100 for 30 min on ice. For 
cell cycle analysis, cells were resuspended in PI/RNase staining solution (0.05 mg/mL 
propidium iodide, 0.1 mg/mL RNase A in 1X PBS) and incubated for 30 min at room 
temperature. For phospho-histone H3S10, phospho-MPM2, and phospho-4E-BP1T37/T46 
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analysis, cells were incubated with the corresponding fluorophore-conjugated antibodies 
for 2 h at room temperature. 
2.2.8 Cell Cycle Synchronization and Mitotic Cell Enrichment 
293 cells were treated with medium containing 0.5 μM nocodazole or 0.5 mM L-
mimosine for 16 h to induce mitotic arrest or G1 arrest, respectively. Mitotic cells were 
enriched by double-thymidine block (2 mM) and release using 293 and U2OS cells or by 
mitotic shake-off (344) using BJ-T cells stably expressing wild-type MCV sT. To block 
cell cycle at late G2, HeLa and U2OS cells were incubated in medium containing CDK1 
inhibitor RO-3306 (10 μM) for 24 h. Cell cycle entry from G2 to mitosis was induced by 
RO-3306 washout. Cells arrested by nocodazole and released from RO-3306 arrest 
were treated with 10 μM of proteasome inhibitor MG132 for 30 min prior to kinase 
inhibitor treatment to retain cells in mitosis. 
2.2.9 In vitro Phosphorylation Assays 
Recombinant GST-4E-BP1 (0.2 μg) (SignalChem) was incubated in a 24-μL reaction 
containing 1X protein kinase buffer (NEB) and 20 units of recombinant CDK1/CYCB1 
(NEB) or 10 μg of mitotic HeLa cell lysate, supplemented with 200 μM ATP and/or 5 μM 
active site kinase inhibitors, for 30 min at 30 °C. HeLa cells were arrested in mitosis by 
treatment with 0.5 μM nocodazole for 16 h and enriched by mechanical shake-off for 
lysis in non-denaturing lysis buffer (50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 1% Triton X-
100, 2 mM Na3VO4 and 2 mM NaF). The reactions were stopped by adding 5X SDS 
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sample buffer to 1X concentration and boiling for 5 min. Reaction samples were then 
subjected to SDS-PAGE and immunoblotting. For in vitro protein dephosphorylation, 
293 cell extracts were incubated with lambda phosphatase in protein 
metallophosphatase reaction buffer (NEB) supplemented with 2 mM MnCl2 for 30 min at 
37 °C. Reactions were stopped by adding 2X SDS sample buffer and then subjected to 
SDS-PAGE and immunoblotting. 
2.2.10 m7GTP Cap Binding Assay 
Shake-off (mitosis-enriched) and adherent cells (mitotic-depleted) from MCV sT-
transduced BJ-T cells or asynchronous BJ-T cells were lysed in buffer (50 mM Tris-HCl, 
pH 7.4, 0.15 M NaCl, 1% Triton X-100, 2 mM Na3VO4 and 2mM NaF) supplemented 
with protease inhibitors (Roche). Lysates (30 μg of total protein) were incubated with 5.0 
μL m7GTP sepharose beads (GE Healthcare) for overnight at 4 °C. Beads were 
collected, washed with lysis buffer, and subjected to SDS-PAGE and immunoblotting. 
25 μg of total protein was loaded as input control (83%). 
2.2.11 In vitro mRNA Synthesis and Translation 
Capped FLuc reporter mRNA was synthesized by the MessageMAX T7 ARCA-Capped 
message transcription kit (Cell Script) using 1 μg pCD-V5-FLuc linearized by MscI as 
template. Purified RNA was polyadenylated using the A-Plus Poly (A) polymerase tailing 
kit (Cell Script). Translation reactions were performed in a final volume of 10 μL 
consisting of 7 μL of nuclease treated rabbit reticulocyte lysate (RRL) (Promega), 0.8 
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pmol of capped and polyadenylated reporter mRNAs and amino acids mixture (50 μM 
each).  GST-4E-BP1 was incubated with either CDK1 or 1 μg/mL BSA in the presence 
of DMSO or 10 μM RO-3306 (see reaction setup for previous section). As a control, 
PBS alone was incubated with the same amount of either DMSO or 10 μM RO-3306. 
Either buffer or pre-treated GST-4E-BP1 (12.4 μL) was added to the rabbit reticulocyte 
lysate reaction mixture. The prepared RRL mixture was incubated for 15 min at 30 °C. 
The reaction was then stopped by adding 10 μL of luciferase lysis buffer to the mixture. 
Translation was measured as firefly luciferase activity.  
2.2.12 Nascent Protein Synthesis Analysis 
BJ-T sT stable cells were labeled with an azide-linked methionine analog, L-
azidohomoalanine (AHA) (Life Technologies) at 25 μM for 45 min in the presence or 
absence of PP242 (5 μM), followed by mitotic shake-off to separate mitotic cells and 
interphase cells. To analyze mitotic cap-dependent translation in U2OS and HeLa cells, 
cells were arrested G2/M boundary by 10 μM RO-3306 treatment for 24 h (345).  After 
30 min of RO-3306 removal, cells were labeled with AHA (25 μM) for 90 min in 
methionine-depleted DMEM medium (Corning Cellgro) after optimization of pre-
experiments. Translation inhibitors (4E1RCat (50 μM) or cycloheximide (100 μg/ml)) or 
DMSO (0.1%) were added to cells with AHA. Cells were trypsinized and fixed in 10% 
formalin for 5 min. Fixed cells were permeabilized in PBS containing 0.1% saponin and 
1% FBS for 30 min at room temperature. Cells were harvested and labeled with the 
Alexa Fluor 488 alkyne using the Click-iT cell reaction buffer kit (Life Technologies). 
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AHA incorporation in cells was analyzed by flow cytometry as a measure for nascent 
protein synthesis in interphase and mitotic cells.  
2.2.13 Statistical Analysis 
One-sided t-test was performed for densitometric analysis of m7GTP pull-down assays 
and two-sided t-test (unequal variances) for in vitro translation assays. A p-value less 



















2.3.1 MCV sT increases mitogenesis by targeting the cellular anaphase 
promoting complex E3 ligase.  
To search for factors contributing to MCV sT-induced transformation, the viral 
oncoprotein was expressed in primary immortalized BJ-tert (BJ-T) fibroblasts. These 
cells displayed a rounded phenotype in culture with increased phospho-histone H3 
serine 10 (pH3S10) phosphorylation, characteristic for mitosis (Figure 12A). Increased 
pH3S10 and increased expression of mitotic markers (including cyclin B1 (CYCB1) and 
phospho-aurora kinase B (pAURKB)) were also observed in 293 cells expressing MCV 
sT (Figure 13). Immunoprecipitation of sT revealed an in vivo complex with the APC/C 
substrate recognition subunit, Cdc20 that was dependent on an intact LSD (Figure 
12B).  MCV sT also interacted with another APC/C substrate recognition subunit, Cdh1, 
but substantial Cdh1-binding occurred with sTmLSD having alanine substitutions at 
residues 91-95, suggesting that sT may bind Cdh1 at other sites in addition to the LSD. 
In line with these results, known APC/C E3 targets, including aurora kinase A (AURKA) 
and AURKB, Skp2, polo-like kinase 1 (Plk1) and CYC A2, showed markedly reduced 
turnover in the presence of sT on cycloheximide (CHX) chase immunoblotting (Figure 
12C). These APC/C E3 targets retained rapid turnover in the presence of empty vector 
or sTmLSD expression. CYCD1, which is not directly regulated by APC/C (346) was 
unaffected by MCV sT or sTmLSD expression. Similarly, MCV sT expression stabilized 
FLAG-tagged AURKA and endogenous CYCB1, but not CYCD1, after nocodazole-
release of 293 cells whereas MCV sTmLSD expression did not (Figure 14).   
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Figure 12. MCV sT increases mitotic entry by targeting APC/C E3-ubiquitin 
ligases. 
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Figure 12 (continued) 
(A) MCV sT induces cellular mitogenesis. BJ-tert (BJ-T) cells stably transduced with 
MCV sT have increased mitotic rounding and a 6 to 18-fold increase in pH3S10+ mitotic 
cells compared to empty vector or sTmLSD transduced cells. (B) MCV sT interacts with 
APC/C E3 ligase substrate recognition subunit Cdc20 and Cdh1 proteins. HA-tagged 
Cdc20 or myc-tagged Cdh1 expression plasmids were co-transfected with MCV sT, 
MCV sTmLSD, or SV40 sT expression plasmids into 293 cells, and immunoprecipitated 
48 h later with anti-HA or anti-myc antibodies, followed by immunoblotting using mixed 
anti-MCV sT (CM8E6) and anti-SV40 sT (PAb419) antibodies. Cdc20 interaction with 
MCV sT was nearly eliminated in the sTmLSD mutant protein while partial interaction was 
retained between MCV sTmLSD and myc-Cdh1 proteins. Weak interaction between SV40 
sT and myc-Cdh1 only was detected. Asterisk indicates immunoglobulin heavy chain. 
(C) APC/C target proteins (AURKA/B, Cdc20, Skp2, Plk1, cyclin A, and claspin) are 
stabilized by MCV sT expression. BJ-T cells were treated with cycloheximide (100 
µg/mL) to inhibit new protein synthesis and harvested at the indicated time points. The 
half-lives of proteins regulated by APC/C are extended by expression of MCV sT but not 
empty vector or MCV sTmLSD controls. Cyclin D is not directly regulated by Cdh1 and its 
half-life was unchanged by MCV sT expression. A representative α-tubulin loading 







Figure 13. MCV sT increases mitogenesis in 293 cells. 
(A) MCV sT expression increases phospho-histone H3S10 (pH3S10) positive mitotic cells. 
(B) MCV sT expression in 293 cells increases mitotic marker expression including 
pAURKA, pAURKB, CYCB1, and pH3S10. Transfected 293 cells were split into two 
fractions for cell cycle profile (A) and mitosis marker immunoblotting (B). 
 
 
Figure 14. MCV sT stabilizes APC/C targets (AURKA and CYCB1) in nocodazole-
arrested 293 cells. 
293 cells co-transfected with FLAG-tagged AURKA and MCV sT, sTmLSD, or empty 
vector, were arrested with nocodazole (0.5 μM) for 15 h, and then treated with CHX 
after nocodazole washout and harvested at different time points for immunoblotting. 
Asynchronous cells for each transfection were used as a control for nocodazole arrest. 
MCV sT, but not sTmLSD or empty vector stabilizes AURKA and CYCB1 proteins in 
metaphase-arrested 293 cells. MCV sT increased FLAG-AURKA and CYCB1 
expression in asynchronous cells, consistent with sT induction of increased 
mitogenesis. 
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2.3.2 MCV sT induces mTOR-independent 4E-BP1 phosphorylation. 
 
Figure 15. MCV sT induces cellular 4E-BP1 hyperphosphorylation. 
(A) MCV sT induces p4E-BP1T37/T46 and p4E-BP1S65/S101 phosphorylation. 4E-BP1 
phosphospecies are named α through δ according to molecular mass. Higher molecular 
mass isoforms, particularly β, γ, and δ were increased following sT expression in 293 
cells and include authentic phosphorylation sites as detected by phospho-specific 
antibodies. A 2D gel fractionation of these same lysates (pH 3-6 isoelectric 
focusing/SDS-PAGE) were aligned to the 1D gel. Arrow heads indicate new 4E-BP1 
isoelectric focusing spots after sT expression detected by p4E-BP1T37/T46, p4E-
BP1S65/S101, and total 4E-BP1 antibodies. (B) MCV sT-induced 4E-BP1 phosphorylation 
is partially resistant to mTOR inhibition. 293 cells were transfected with MCV sT, sTmLSD, 
or empty vector expression plasmids for 48 h, treated with the mTOR-inhibitor PP242 
and harvested at the indicated time points. MCV sT depends on an intact LSD region to 
maintain PP242-resistant 4E-BP1 phosphorylation. Representative results are shown 
from three independent experiments. 
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We next examined the role of MCV sT in 4E-BP1 hyperphosphorylation. 4E-BP1 
hyperphosphorylation isoforms are named α through δ according to ascending 
molecular mass (Figure 15A) (157). Most notable was the appearance of the highest 
molecular mass form, δ, containing phosphorylation marks at T37/T46 and S65/S101, 
after transfection of the sT expression vector into 293 cells, as previously described 
(170). A two-dimensional (2D) gel immunoblot (Figure 15A, right panel) aligned to the 
corresponding 1D SDS PAGE immunoblot shows that during MCV sT expression, a 
new phospho-isoform appears at the δ position (arrows) staining for p4E-BP1T37/T46 and 
p4E-BP1S65/S101. MCV sT expression prolonged 4E-BP1 phosphorylation (Figure 15B) 
in the presence of the mTOR inhibitor PP242 (347) compared to empty vector control 
and sTmLSD transfected cells, indicating that δ-4E-BP1 phosphorylation may be 
independent of mTOR kinase activity. 
2.3.3 CDK1/CYCB1 directly phosphorylates 4E-BP1, in the presence and absence 
of sT, to the δ isoform during mitosis.   
4E-BP1 phosphorylation is induced by microtubule assembly inhibitors such as 
nocodazole and paclitaxel that arrest cells in mitosis (208, 243). To assess the role of 
various kinases on mitotic 4E-BP1 phosphorylation, nocodazole-treated HeLa mitotic 
cell lysates were reacted with recombinant GST-4E-BP1 and kinase inhibitors, including 
PP242 (mTORC1 and mTORC2), RO-3306 (CDK1), and VX-680 (pan AURK) (Figure 
16A). GST-4E-BP1 was robustly phosphorylated at authentic sites by mitotic HeLa 
lysates, and this was reversed by inhibition of CDK1 but not by mTOR or AURK 
inhibition.   
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Figure 16 (continued) 
(A) CDK1 inhibition in mitotic lysates reduces 4E-BP1 phosphorylation. Mitotic HeLa cell 
lysates (10 µg) enriched by nocodazole arrest, were mixed with 0.2 µg GST-4E-BP1, 
reacted for 30 min at 30 °C in the presence or absence of 5 µM mTOR (PP242), CDK1 
(RO-3306), or AURK (VX-680) kinase inhibitors and then immunoblotted with antibodies 
as shown. ATP-dependent 4E-BP1 phosphorylation was sensitive to CDK1 inhibitor but 
resistant to mTOR and AURK inhibitors. Equal loading of total 4E-BP1, CYCB1, and α-
tubulin is shown. Representative results are shown from three independent 
experiments. (B) Recombinant CDK1/CYCB1 kinase phosphorylates GST-4E-BP1 at 
the known regulatory residues T37/T46, S65/S101, and T70. CDK1/CYCB1 (20 units) 
was mixed with bacterial expressed GST-4E-BP1 in kinase reaction buffer for 30 min at 
30 °C, and immunoblotted with phospho-specific antibodies. ATP-dependent 4E-BP1 
phosphorylation by CDK1/CYCB1 occurred at phospho-specific sites and was sensitive 
to the CDK1 active site inhibitor RO-3306. Representative results shown from two 
independent experiments. (C) δ-4E-BP1 is induced during mitosis and inhibited by a 
CDK1 inhibitor. 293 cells were transfected with empty vector or MCV sT, and arrested 
for 20 h with DMSO (asynchronous), nocodazole (prometaphase), and mimosine (late 
G1). Cells treated were treated at 16 h with kinase inhibitors (5 µM PP242 or 10 µM 
RO-3306 + 10 µM MG132) as indicated. MCV sT induces δ-4E-BP1 in asynchronous 
cells sensitive to RO-3306 but not PP242. Nocodazole-arrest induces similarly RO-3306 
sensitive and PP242 resistant δ-4E-BP1 even in the absence of sT, whereas δ-4E-BP1 
is only weakly induced by sT in mimosine-arrested cells. Markers for mitosis (pH3S10, 
CYCB1), a CDK1 substrate (cdc25C), and an mTORC1 downstream substrate 
(pS6S242/S244) showed active drug treatments. Representative results are shown from 
two independent experiments. (D) δ-4E-BP1 phosphorylation during mitosis occurs in 
the absence of active mTOR. U2OS cells were arrested at G2/M boundary with 10 µM 
RO-3306 for 24 h, released by washing and harvested at the time points shown. Cells 
were treated for 3 h pre-release with DMSO or 5 µM PP242. In the absence of mTOR 
inhibition, no δ-4E-BP1 is found at 0 h but accumulates, together with β and γ isoforms, 
during mitotic transit. During PP242 inhibition, δ-4E-BP1 still accumulates during mitosis 







Evidence that CDK1 is responsible for δ-4E-BP1 mitotic phosphorylation was 
also obtained by treatment of nocodazole-arrested HeLa cells with the CDK1 inhibitor 
RO-3306 (Figure 17A). δ-4E-BP1 hyperphosphorylation could not be fully restored by 
RO-3306/MG132 co-treatment. A technical issue in using mitotic kinase inhibitors to 
assess 4E-BP1 phosphorylation is the occurrence of mitotic slippage, a side effect of 
kinase inhibition concurrently causing enforced exit from mitosis with general loss of 
mitotic kinase activities (345, 348). Mitotic slippage can be prevented by simultaneous 
inhibition of APC/C-mediated protein degradation with the proteasome inhibitor MG132, 
which in effect “freezes” the mitotic phenotype. Like RO-3306, treatment of nocodazole-
arrested HeLa cells with the AURK inhibitor VX-680 also eliminated δ-4E-BP1 
phosphorylation (Figure 17B). Unlike RO-3306, however, this was completely reversed 
by co-treatment with VX-680/MG132, suggesting that AURK inhibition effects on 4E-
BP1 phosphorylation are due to mitotic slippage. Extensive in vitro phosphorylation 
studies also failed to reveal evidence for direct 4E-BP1 phosphorylation by purified 
AURKB (pers. comm., SMA Lens and RCC Hengeveld, UMC-Utrecht). To confirm direct 
4E-BP1 phosphorylation by CDK1/CYCB1, we generated an in vitro phosphorylation 
reaction using purified CDK1/CYCB1 and GST-4E-BP1 (Figure 16B). CDK1 
phosphorylation of 4E-BP1 was ATP-dependent and inhibitable by RO-3306. CDK1 
phosphorylation occurred at the previously-described T70 residue (207) as well as at 
authentic 4E-BP1 phosphorylation sites, including T37/T46, S65/S101 that are known to 





Figure 17. Mitotic slippage with mitotic kinase inhibition. 
(A) CDK1 inhibition during nocodazole/MG132 treatment fails to fully restore δ-4E-BP1 
hyperphosphorylation. Notably, residual 4E-BP1 phosphorylation during RO-3306 
treatment is further reduced by PP242 treatment suggesting that mTOR 
phosphorylation may partially restore 4E-BP1 phosphorylation under conditions of 
CDK1 inhibition. Cdc25C is a direct phosphorylation target for CDK1. (B) The same 
experiment as in (A) was repeated using the pan-AURK inhibitor VX-680. Treatment 
with VX-680 reduces 4E-BP1 hyperphosphorylation in nocodazole-arrested HeLa cells 
by inducing mitotic exit. When HeLa cells were arrested with nocodazole (0.5 μM) for 16 
h and treated with the proteasome inhibitor MG132 (10 μM) to prevent APC/C-mediated 
mitotic exit, VX-680 no longer prevents 4E-BP1 hyperphosphorylation but does inhibit 
AURKB-mediated phosphorylation of H3S10. 
 
Mitotic δ-4E-BP1 phosphorylation was also examined in nocodazole-arrested 
293 cells in the presence of CDK1 and mTOR inhibitors (Figure 16C). MG132 was 
added to nocodazole-arrested cells 30 min before RO-3306 treatment to prevent CDK1 
inhibition-induced mitotic slippage (348). In this experiment, pH3S10+ mitotic cells 
comprised ~0.9% of the total asynchronous (no cell cycle arrest) cell population (Figure 
16C, left panel and Figure 13). MCV sT expression promotes formation of PP242-
resistant δ-4E-BP1 that is lost after treatment with RO-3306. Notably, S6S242/244 
phosphorylation, a known phosphorylation mark for mTORC1 kinase activity (349, 350), 
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is nearly ablated by PP242 but not by RO-3306. These results are consistent with sT 
induction of δ-4E-BP1 through CDK1 rather than mTOR kinase activity.   
Distinctive 4E-BP1 phosphorylation patterns were seen during nocodazole 
(prometaphase) and mimosine (late G1) cell cycle arrest (Figure 16C). During 
nocodazole arrest, the δ-4E-BP1 isoforms became prominent even in the absence of 
MCV sT expression. In contrast, δ-4E-BP1 isoforms were nearly absent under all 
conditions for cells arrested in G1 by mimosine. Whereas δ-4E-BP1 was resistant to 
mTOR inhibition, CDK1 inhibition during nocodazole mitotic arrest ablated δ-4E-BP1. 
These results were confirmed in HeLa cells treated with nocodazole and kinase 
inhibitors (Figure 17). 
 
Figure 18. δ-4E-BP1 phospho-isoform expression in sT-expressing mitotic cells. 
(A) BJ-T cells transduced with MCV sT can be enriched for mitotic and non-mitotic cell 
populations by mechanical shake-off. Non-adherent cells are enriched for pH3S10 
positivity from 1.8% to 66% after shake-off, while remaining pH3S10 positivity was 
reduced to less than 1% for adherent cells. (B) Immunoblotting for δ-4E-BP1 reveals 
that δ-4E-BP1 is present only in the mitotic fraction, confirmed by mitotic markers 
pAURKA, pAURKB, pH3S10, and pMPM2. Adherent cells, positive for CYCE1, are 
negative for δ-4E-BP1. Representative result is shown of three independent 
experiments. 
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To confirm these findings in the absence of chemical inhibitors, we used 
mechanical shake-off to isolate mitotic cells from sT-expressing BJ-T cells (Figure 18). 
This maneuver enriched the mitotic cell fraction from ~2% to ~66% as determined by 
flow cytometry with propidium iodide (PI) and pH3S10 staining (Figure 18A). Shake-off 
cells exclusively expressed the δ isoform whereas adherent cells expressed only α, β, 
and γ isoforms of 4E-BP1 (Figure 18B). In vitro lambda phosphatase treatment of sT-
expressing and nocodazole-arrested 293 cell lysates showed that the high molecular 
mass 4E-BP1 isoforms, including the α, β, γ, and δ isoforms, are formed as a result of 
phosphorylation rather than another type of post-translational modification (Figure 19). 
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Figure 19. 4E-BP1 β, γ, and δ isoforms are completely lost after lambda 
phosphatase treatment. 
 
Although PP242-inhibitable mTOR kinase activity contributes to mitotic 4E-BP1 
phosphorylation, particularly for lower molecular mass α and β forms (Figure 16C), 
mTOR may be dispensable for mitotic 4E-BP1 hyperphosphorylation under some 
conditions. U2OS cells were arrested at the G2/M boundary for 24 h using 10 μM RO-
3306 (345, 351) (Figure 16D). After RO-3306 removal, cells progressed through mitosis 
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with most exiting mitosis 3 h after RO-3306 release. PP242 pre-treatment markedly 
reduced pS6S242/244 but not δ-4E-BP1, consistent with mTOR-independent 
phosphorylation of 4E-BP1 during mitosis. Similar results were seen with HeLa cells 
(data not shown) while 293 cells failed to arrest in G2 with RO-3306 and could not be 
examined. 
2.3.4 δ 4E-BP1 is induced in mitosis during normal cell cycling. 
Nocodazole-arrest experiments suggest that δ-4E-BP1 accumulates during mitosis 
even in the absence of MCV sT expression. To confirm this in the absence of drug 
treatment, 293 cells were synchronized by double-thymidine block and release, 
harvested at sequential time points and immunostained for pH3S10 and p4E-BP1T37/T46 
(Figure 20A). For each time point after release, cells were pre-treated with PP242 or 
DMSO vehicle control 1 h prior to harvesting.   
Flow cytometry showed peak pH3S10+ mitotic entry occurring reproducibly at 10 h, 
which began to diminish by 12 h after release (Figure 20A and Figure 21). This same 
pattern occurred with PP242 pre-treatment, although mitotic entry was more abundant 
at 8 h post-release. Unexpectedly, pH3S10+ mitotic 293 cells formed an orthogonal 
population with the highest per cell saturation levels of p4E-BP1T37/T46 compared to any 
other stage of the cell cycle. PP242 pre-treatment reduced p4E-BP1T37/T46+ staining for 
interphase cells at 2-8 h (note leftward shift for p4E-BP1T37/T46+ staining among pH3S10- 
cells) consistent with mTOR regulation of 4E-BP1. At peak mitotic entry (8-10 h post 
release), however, pH3S10+ cells were resistant to loss of p4E-BP1T37/T46+ staining with 
PP242 treatment.   
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Figure 20. 4E-BP1 is hyperphosphorylated to the δ isoform during mitosis. 
(A) pH3S10+ mitotic 293 cells have higher levels of p4E-BP1T37/T46+ saturation than cells 
in other portions of the cell cycle. Dual flow cytometry staining for pH3S10 and p4E-
BP1T37/T46 was performed on 293 cells synchronized by double-thymidine block and 
release, which show peak mitotic entry at 10 h post-release. Vertical bar represents the 
centroid for p4E-BP1T37/T46+ fluorescence staining at time 0 h. To determine if 4E-BP1 
phosphorylation depends on mTOR activity, cells were also treated 1 h prior to 
harvesting with 5 µM PP242. Mitotic cells formed an orthogonal pH3S10+/p4E-BP1T37/T46+ 
population having high levels of inactivated (phosphorylated) 4E-BP1 that were not 
dependent on mTOR activity. In contrast, interphase pH3S10- cells were largely mTOR-
inhibition sensitive. PP242 treatment increases mitotic entry at 8 h post-release. (B) 
PP242-resistant δ-4E-BP1 is formed during peak mitotic entry. Protein lysates were 
collected from cells in (A) and immunoblotted for phospho-4E-BP1 and phospho-H3S10. 
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Figure 21. Flow cytometry, with PI and phospho-H3S10 staining, of 293 cells 
synchronized by double-thymidine release. 
 
Immunoblots performed on these same cell fractions at each time point (Figure 
20B) showed prominent α-γ 4E-BP1 phosphorylation at early time points (0-6 h), which 
was sensitive to mTOR inhibition. The δ isoform emerged 8-12 h after release, 
corresponding to maximum pH3S10+ and p4E-BP1T37/T46+ staining, and was resistant to 
PP242 inhibition. Similar results, but with a less abundant orthogonal pH3S10+/p4E-
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Figure 22. δ-4E-BP1 induction during mitosis in synchronized U2OS cells. 
(A) Flow cytometry, with PI and phospho-H3S10 staining, of U2OS cells synchronized by 
double-thymidine release indicates maximum mitotic entry 10 h post-release, in the 
presence and absence of mTOR inhibition by PP242. Dual phospho-H3S10 and 
phospho-4E-BP1T37/T46 positive mitotic cells form an orthogonal cell population that 
peaks at 10 h and is reduced by 12 h post-release. (B) Protein lysates from (A) were 
immunoblotted for phospho-4E-BP1 and phospho-H3S10. The δ-4E-BP1 isoform is 
apparent 6-12 hours after release, corresponding to pH3S10 positivity. This 4E-BP1 
isoform is resistant to PP242 in U2OS cells.   
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2.3.5 CDK1 activates cap-dependent translation during mitosis. 
According to the existing model for 4E-BP1-regulated protein synthesis, high levels of 
p4E-BP1T37/T46 are predicted to promote cap-dependent translation during pH3S10+ 
mitosis (30). We directly examined this by using cap-binding assays for mitosis-enriched 
and -depleted cells and by employing a new flow cytometry method designed to directly 
measure single-cell cap-dependent protein synthesis.   
We performed m7GTP cap resin pulldown assays to assess the functional 
correlates of our flow cytometry and western blot findings. Highly-enriched mitotic BJ-T 
cells expressing MCV sT, isolated by shake-off (non-adherent), showed m7GTP cap 
binding to eIF4G that was unaffected by PP242 treatment (Figure 23A). In contrast, 
although interphase-enriched BJ-T cells (adherent), had comparable levels of eIF4G, 
eIF4G cap binding remained sensitive to PP242. Input 4E-BP1 protein from mitosis-
enriched cells was almost exclusively in the δ-4E-BP1 isoform. This is consistent with 
mTOR-independent cap-binding during mitosis and mTOR-dependent cap-binding 
during interphase. Qualitatively similar results were found for HeLa cells using G2/M 
arrest enrichment and shake-off (Figure 24). For mitosis-enriched HeLa cells, modest 
but reproducible reduction in eIF4G-m7GTP cap association was present with RO-3306 
treatment alone but not PP242 treatment alone. Combined RO-3306 and PP242 
treatment nearly eliminated eIF4G association to m7GTP. These results were confirmed 
by metabolic labeling using the Click-IT methionine analog L-azidohomoalanine (AHA) 
to measure nascent protein synthesis (Figure 23B). In this assay, cells were incubated 
with AHA for 90 min (352), in the absence or presence of PP242, in methionine-
depleted medium, and then subjected to mitotic shake-off. Newly synthesized protein 
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was then labeled with Alexa Fluor 488-alkyne by the copper(I)-catalyzed azide-alkyne [3 
+ 2] cycloaddition (Click-iT) reaction (353)) and measured by flow cytometry. Co-
staining for pH3S10 allowed segregation of individual cells into “mitotic” (pH3S10+) and 
“interphase” (pH3S10-) populations. Up to 74% of DMSO-treated mitotic cells were AHA 
positive in comparison to 91% of DMSO-treated interphase cells with AHA positivity. 
PP242 treatment reduced new protein synthesis for pH3S10- interphase BJ-T cells but 
had no effect on protein synthesis for pH3S10+ mitotic BJ-T cells (Figure 23B). Similar 
analyses using double thymidine block and release synchronization of 293 cells, 
however, revealed that PP242 reduced new protein synthesis for both mitotic and 
interphase cells (Figure 25), suggesting that PP242 resistance may be cell line specific.   
We next generated capped, polyadenylated luciferase reporter mRNA using T7 
polymerase (354, 355) and performed in vitro translation in commercial rabbit 
reticulocyte lysates to measure cap-dependent translation (Figure 23C). Addition of 
4E1RCat (356), a cap-dependent translation inhibitor that prevents eIF4F formation, 
virtually abolished translation. Addition of recombinant GST-4E-BP1 reduced cap-
dependent translation in the reticulocyte lysates to ~20% of buffer control (Figure 23C). 
This inhibition was reduced to 45% of buffer control when GST-4E-BP1 was 
phosphorylated (p4E-BP1) by a CDK1/CYCB1 kinase reaction. This reversal of 







Figure 23. eIF4F formation on the m7GTP cap and direct measurement of cap-
dependent protein translation during mitosis (M) and interphase (I). 
(A) eIF4F formation on the m7GTP cap is PP242 independent for mitosis-enriched cells 
but PP242 sensitive for mitosis-depleted cells. BJ-T cells expressing MCV sT were 
harvested by mitotic shake-off to enrich for mitotic (non-adherent) and non-mitotic 
(adherent) populations, and compared to asynchronous empty vector BJ-T cells without 
shake-off. Lysates were bound to m7GTP-resin, precipitated and immunoblotted.  
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Figure 23 (continued) 
Mitosis-enriched cell eIF4G-binding, as well as 4E-BP1-binding, to the eIF4E/cap 
complex was unaffected by mTOR inhibition. For mitosis-depleted cells, eIF4G-binding 
was reduced and 4E-BP1-binding was increased by mTOR inhibition. Representative 
results from two independent experiments are shown. (B) Nascent protein synthesis 
during mitosis is resistant to mTOR inhibition in BJ-T cells.  BJ-T cells stably expressing 
sT were labeled with azido-homoalanine (AHA) for 45 min in methionine-depleted 
media, separated by mitotic shake-off as in (A), reacted with Click-iT Alexa Fluor 488 
alkyne after permeabilization, and new protein synthesis measured by flow cytometry.  
Relative mitotic protein synthesis was determined by dividing percentage of pH3S10+-
AHA+ cells by percentage of total pH3S10+ cells.  Likewise, interphase protein synthesis 
was determined by dividing percentage of pH3S10--AHA+ cells by percentage of total 
pH3S10- cells. Approximately 91% of pH3S10- adherent interphase cells showed AHA 
incorporation that was sensitive to mTOR inhibition. Only 74% of pH3S10+ positive 
mitotic cells were positive for AHA uptake but this new protein synthesis was resistant to 
PP242 treatment. Baseline fluorescence was determined in asynchronous BJ-T cells 
without AHA incubation. (C) In vitro capped mRNA translation is inhibited by 4E1RCat 
and activated by CDK1/CYCB1. Capped and polyadenylated luciferase mRNA was 
generated in a T7 polymerase reaction and used to generate luciferase protein in a 
rabbit reticulocyte lysate. 4E1RCat abolished luciferase translation while addition of 
GST-4E-BP1 reduced translation to 15% of buffer control (averages for three 
independent experiments with SEM shown). When GST-4E-BP1 was phosphorylated 
by CDK1/CYCB1 in kinase reaction buffer, translation increased to 43% of buffer 
control. This effect was eliminated by RO-3306 pre-treatment. Insert shows GST-4E-
BP1 phosphorylation immunoblot. (D) Mitotic translation is primarily cap-dependent for 
HeLa and U2OS. HeLa or U2OS cells were synchronized for 24 h at the G2/M 
boundary, released by washing and incubated with the 25 µM of AHA for 90 min in 
methionine-depleted media, and then harvested 2 h after release. Harvested cells were 
permeabilized and reacted with Alexa Fluor-488 alkyne to measure AHA incorporation 
into protein. DMSO vehicle control, CHX (100 µg/ml) or 4E1RCat (50 µM) were added 
together with AHA 30 min after release. M: mitotic pH3S10+ cells; I: interphase pH3S10- 
cells. Vertical bar represents maximum AHA incorporation after CHX translation 
inhibition. Fewer mitotic (26%) than interphase (42%) HeLa cells were positive for new 
protein synthesis but all cells were sensitive to 4E1RCat inhibition of cap-dependent 
translation. For U2OS, cell numbers positive for total mitotic and interphase translation 
were identical (42%) and cap-dependent translation represented 73% and 85% of 
mitotic and interphase translation, respectively. Bottom panel shows 4N gated AHA 
positivity for treated cells shows that 4E1RCat inhibition (cap-dependent) is similar to 




Figure 24. eIF4F formation on the m7GTP cap is inhibited by CDK1 inhibition in 
mitosis-enriched HeLa cells. 
HeLa cells were enriched or depleted for mitosis by G2/M boundary arrest 
synchronization and shake-off. For mitosis-enriched cells, 4E-BP1 binding to the 
m7GTP resin was increased by RO-3306 treatment alone. RO-3306 but not PP242 
significantly inhibits eIF4G pulldown by m7GTP resin in HeLa cells. Near-complete 
inhibition, however, was present with combined PP242 and RO-3306 (PP+RO), 
suggesting cooperativity for mTOR and CDK1 in mitosis-enriched cells. For mitosis-
depleted HeLa, PP242 alone inhibits eIF4G binding and activates 4E-BP1 binding to the 
m7GTP resin. Error bars are SEM, asterisks denote significant comparisons by one-
sided t test with p < 0.05 while n.s. denotes non-significant change. Quantitative LICOR 
immunoblotting shown is representative for one of three independent experiments used 
to generate average and SEM values for cap-binding. 
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Figure 25. The 293 cell-nascent protein synthesis is sensitive to PP242. 
Double-thymidine release was performed for 293 cells. Drug treatment (PP242 at 5 μM 
and CHX at 100 μg/mL) was given at 8.5 h and AHA (25 μM) at 9 h, 15 min post-
release, and then cells were harvested at 10 h. The protein synthesis inhibitor CHX 
served as a negative control for AHA incorporation, and pH3S10 was used to measure 
mitotic activity. New protein synthesis is similar for both phospho-pH3S10–positive and 
phospho-pH3S10–negative mock-treated cells, indicating that protein synthesis is not 
inhibited during mitosis for 293 cells. Unlike BJ-T, PP242 reduced AHA incorporation for 
both mitotic and non-mitotic populations. 
 
Measurement of cap-dependent protein synthesis during mitosis was directly 
determined for HeLa and U2OS cells after G2 release and synchronization using our 
AHA assay in cells treated with 4E1RCat (Figure 23D). Co-staining for pH3S10 allowed 
segregation of cells into mitotic (pH3S10+) and interphase (pH3S10-) populations. 
Nonspecific AHA incorporation was determined using the ribosome translation 
elongation inhibitor CHX (Figure 23D, vertical lines) and new protein synthesis was 
reflected by AHA fluorescence above this baseline.   
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Figure 26. Nocodazole inhibits mitotic protein translation. 
AHA incorporation is present for both mitotic (pH3S10+) and interphase (pH3S10-) 293 
cells but is markedly reduced when pH3S10+ cells are treated with 0.5 µM nocodazole.  
No significant change in AHA incorporation was noted for pH3S10- cells with nocodazole 
treatment. Dotted lines represent threshold between pH3S10+ and pH3S10- cells, with 
active or inhibited new protein synthesis. M: mitotic pH3S10+ cells; I: interphase pH3S10- 
cells. 
 
Like BJ-T cells, fewer (27%) mitotic HeLa cells were positive for new protein 
synthesis compared to interphase (46%) HeLa cells (Figure 23D). In contrast, 
percentages of mitotic and interphase U2OS cells with new protein synthesis were 
identical (42% of mitotic and interphase cells). For both cell lines, however, nearly all 
new protein synthesis in both mitosis and interphase was cap-dependent and sensitive 
to 4E1RCat treatment. Preliminary analyses revealed that MG132 treatment 
nonspecifically inhibited protein synthesis as previously reported (357), preventing us 
from accurately measuring the effects of CDK1 inhibition on mitotic translation under 
conditions that inhibit mitotic slippage. Using direct AHA uptake, however, we could 
confirm that nocodazole treatment inhibits mitotic protein synthesis (Figure 26).  
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2.4 DISCUSSION 
Tumor viruses have been central to cell biology because their oncogenes allow 
interrogation of specific cell proliferation and survival pathways. Among many critical 
findings, viral oncoproteins have been essential to the discovery of cellular oncogenes 
(358) and the tumor suppressor p53 (287, 311, 359); the characterization of the G1/S 
checkpoint (312) and the Akt-mTOR pathway (360); and identification of common innate 
immune and tumor suppressor signaling networks (361). MCV sT, an oncoprotein for 
MCC, induces mTOR-resistant 4E-BP1 hyperphosphorylation and cell transformation 
(170), which led us to investigate mTOR-independent 4E-BP1 signaling and cap-
dependent translation in mitosis. 
In addition to targeting Fbw7 (338), MCV sT inhibits APC/C E3 ligases, as well as 
other specific E3 ligases (unpublished), and induces mitogenesis in sT-expressing cells. 
One consequence of this is increased mitotic CDK1/CYCB1 activity that is responsible 
for 4E-BP1 phosphorylation and δ-4E-BP1 formation. Caution is appropriate in 
interpreting our data since mitotic kinase inhibition can cause mitotic slippage and exit 
from the mitotic phenotype. Considerable effort by our group was devoted to evaluating 
AURKA and AURKB as potential 4E-BP1 mitotic kinases since AURK inhibitors (e.g. 
VX-680, MK-5108 and AZD-1152) also reduce 4E-BP1 hyperphosphorylation during 
mitosis. This was reversible, however, by co-treatment with MG132 to prevent APC/C-
mediated mitotic egress and we have no evidence that AURKs are directly responsible 
for 4E-BP1 phosphorylation. In contrast, there is considerable evidence from this study 
and others (207, 208) to indicate that CDK1/CYCB1 is a bona fide kinase for 4E-BP1.  
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This study suggests an alternative pathway for CDK1/CYCB1 regulated cap-
dependent translation during mitosis (Figure 27). We find that mitotic 4E-BP1 is highly 
phosphorylated at the priming residues T37 and T46 in pH3S10+ cells, which runs 
counter to what would be predicted if cap-dependent translation is reduced during 
mitosis through an mTOR-related mechanism. The high molecular mass δ-4E-BP1 
isoform is specific to mitosis and our data indicates that this results from CDK1-
mediated phosphorylation. While δ-4E-BP1 can form under mitotic conditions in which 
mTOR is inhibited, it seems likely that mTOR cooperates with CDK1/CYCB1 to 
generate the mitotic δ-4E-BP1 by phosphorylating lower molecular mass α, β, and γ 
isoforms that may be precursors to the δ-4E-BP1 isoform. Another limitation to our 
study is that we measure only 4E-BP1 phosphorylation but not δ-4E-BP1 
dephosphorylation or turnover. These are likely to affect steady-state p4E-BP1 levels as 
well.   
Our findings contrast with studies suggesting that loss of mTOR activity leads to 
inhibition of mitotic eIF4G cap-association and cap-dependent translation. We see that 
cap-dependent protein translation is sustained during mitosis using a pulse flow 
cytometry approach. Pharmacological (4E1RCat) cap-dependent translation inhibitor 
used on three cell lines under two different mitotic-enrichment conditions provide 
evidence that this effect is generalizable. To our knowledge, our AHA incorporation 
assays are the first time that cap-dependent translation has been directly measured in 
mitotic and interphase cells. Like [35S]-methionine incorporation studies, AHA 
incorporation measurements required incubation of cells in low methionine media. While 
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most mitotic translation is cap-dependent in all of the cell lines tested, differences in 
relative mitotic and interphase translation were present between cell lines.  
 
 
Figure 27. Model for cell cycle dependent 4E-BP1 regulation of cap-dependent 
mRNA translation. 
Interphase 4E-BP1 is inhibited by mTORC1 kinase, whereas CDK1/CYCB1 is primarily 
responsible for δ-4E-BP1 inactivation during mitosis. 
 
We suspect that technical issues, that have only recently been resolved, explain 
differences between our studies and those of others. Measurement of mitotic protein 
translation (both cap-dependent and independent) has relied on separation of mitotic 
and interphase cells in bulk culture, often using nocodazole-induced mitotic enrichment. 
We confirm that nocodazole inhibits mitotic translation for synchronized 293 cells. This 
has been ascribed by Coldwell et al. (243) to inhibitory phosphorylation of eIF2 and 
eIF4GII by nocodazole downstream to 4E-BP1 regulation. This is consistent with our 
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findings that nocodazole both promotes δ-4E-BP1 and inhibits mitotic translation. We 
have not tested other mitotic-arrest compounds (e.g., paclitaxel) to determine if they 
have similar limitations. A second technical challenge is that mitotic cells represent a 
small fraction of the total cell population. Contamination with interphase cells is nearly 
inevitable in mitotic enrichment protocols and will dramatically alter conclusions such as 
the role of mTOR in regulating 4E-BP1 during mitosis. In our experience, flow cytometry 
can help to resolve this dilemma by directly measuring mitotic status (pH3S10 or pMPM2 
status) in cells while simultaneously determining translation regulator status, such as 
p4E-BP1T37/T46. Finally, newly-developed classes of cap-dependent translation 
inhibitors, such as 4E1RCat, now allow direct determination of cap-dependent 
translation. When used in combination with AHA incorporation, direct measurement of 
mitotic cap-dependent translation can be determined.  
Both nocodazole and PP242 are nonetheless important inhibitors to measure 4E-
BP1 phosphorylation and translation during mitosis. As indicated, nocodazole does not 
interfere with δ-4E-BP1 formation and is useful for accentuating mitotic regulation of 4E-
BP1. mTOR regulates translation through ribosomal biosynthesis as well as direct 
phosphorylation of translation machinery components downstream from 4E-BP1, such 
as eIF4B (362) and eEF2 elongation factor (363). Further, eIF4B regulation by 14-3-3σ 
may also play a role in later stages of mitotic protein translation and may be missed in 
our study of early mitosis (241). Thus, PP242 may affect mitotic translation by acting 
downstream to 4E-BP1. We also find evidence that in most cells mTOR typically acts in 
concert with CDK1/CYCB1 to promote mitotic cap-dependent translation.   
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Cap-dependent translation of preformed mRNAs provides rapid regulation of 
gene expression that may be required for rapid cellular responses, such as transit 
through mitosis. These changes generally cannot be accurately measured by standard 
mRNA expression techniques. Mounting evidence suggests that dysregulated cap-
dependent translation from aberrant PI3K-Akt-mTOR and MEF-RAF-MEK-ERK 
signaling contributes to cancer cell transformation (223, 271). Regardless of the 
contribution of activated cap-dependent translation to cancer cell transformation, such 
as in MCV-positive MCC, our findings point towards the possibility that combined mTOR 
and CDK1/CYCB1 inhibition may prove useful for cancer treatment, particularly for 
mTOR-inhibitor resistant cancers.    
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3.0  MITOTIC PROTEIN KINASE CDK1 PHOSPHORYLATION OF MESSENGER 
RNA TRANSLATION REGULATOR 4E-BP1 SER83 MAY CONTRIBUTE TO CELL 
TRANSFORMATION 
Work described in this chapter was published in the Proceedings of the Academy of 
Sciences 
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with authors Celestino Velásquez, Erdong Cheng, Masahiro Shuda, Paula J. 
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Jacobs, Patrick S. Moore, and Yuan Chang 
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This chapter demonstrates that 4E-BP1 hyperphosphorylation is a generalizable 
phenomenon in mitotic cells and describes the novel phosphorylation of 4E-BP1 Ser83 
by the mitotic CDK1 kinase and its potential contribution to cell transformation. mTOR-
directed 4E-BP1 phosphorylation promotes cap-dependent translation and 
tumorigenesis. During mitosis, CDK1 substitutes for mTOR and fully phosphorylates 4E-
BP1 at canonical sites (T37, T46, S65, and T70) as well the non-canonical S83 site 
resulting in a mitosis-specific hyperphosphorylated δ isoform. Colocalization studies with 
a phospho-S83 specific antibody indicate that 4E-BP1 S83 phosphorylation 
accumulates at centrosomes during prophase, peaks at metaphase, and decreases 
through telophase. While S83 phosphorylation of 4E-BP1 does not affect general cap-
dependent translation, expression of an alanine substitution mutant 4E-BP1.S83A 
partially reverses rodent cell transformation induced by Merkel cell polyomavirus (MCV) 
small T (sT) antigen viral oncoprotein. In contrast to inhibitory mTOR 4E-BP1 
phosphorylation, these findings suggest that mitotic CDK1-directed phosphorylation of 
δ-4E-BP1 may yield a gain-of-function, distinct from translation regulation, that may be 









Eukaryotic cells synthesize proteins primarily through cap-dependent mRNA translation. 
This process is mediated by a complex of eukaryotic translation initiation factors, eIF4F, 
which assemble on the 7-methyl-guanosine cap of mRNA (3). eIF4E occupation of the 
5’ cap of mRNA results in the recruitment of eIF4F complex members—mainly eIF4G, 
eIF4A, and eIF3—which in turn attract the 40S ribosome and the rest of the translation 
machinery (3). A set of small binding proteins called eIF4E-binding proteins (4E-BPs)—
4E-BP1, 4E-BP2, and 4E-BP3—inhibit cap-dependent translation by interacting with the 
cap-bound eIF4E (144). The best-characterized and predominant eIF4E binding protein 
is 4E-BP1, which has a molecular weight of 15 kDa and is expressed in most tissues 
(144). 4E-BP1 competes with the complex scaffold protein eIF4G for the same binding 
site on eIF4E and prevents eIF4F cap complex assembly and ribosome recruitment 
(144).  
 The PI3K-AKT pathway regulates the translation repressor function of 4E-BP1 by 
activating the mammalian target of rapamycin (mTOR) kinase (144). Stimulated by 
metabolic and growth-related signals, mTOR phosphorylates 4E-BP1 and decreases its 
affinity for eIF4E in favor of translation (143). Priming phosphorylations at Thr(T)37 and 
T46 are required for subsequent phosphorylations at T70 and Ser(S)65 (143). Double 
alanine substitutions of the critical T37 and T46 priming sites render a constitutively 
active protein that strongly binds eIF4E and is insensitive to mTOR inhibition (153). 
Three additional potential phosphorylation sites have been identified—S83, S101, and 
S112—whose regulation mechanisms remain unclear (154, 175, 176). 
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 Accumulating evidence indicates that dysregulation of cap-dependent translation 
through 4E-BP1 inactivation contributes to malignant transformation (143, 144). 
Frequently activated in cancers, the PI3K-AKT-mTOR pathway leads to enhanced 4E-
BP1 phosphorylation and, thus, diminished translation repression activity (159, 246, 
340); and multiple reports have found expression of high levels of phosphorylated 4E-
BP1 in tumors (143). Overexpression of eIF4E transforms cells by enhancing translation 
of oncogenic mRNA, which can be reversed by ectopic expression of a non-
phosphorylatable 4E-BP1 priming site mutant (254, 257, 268). Resistance of various 
cancers to mTOR inhibitor treatment indicates that other pathways are implicated in 4E-
BP1 inactivation (364). Several serine/threonine kinases have been shown to 
phosphorylate 4E-BP1, such as p38 MAPK, ERK, PIM2, ATM, CDK1, PLK1, LRRK2, 
GSK3β, and CK1ε (163, 207, 210, 211, 215, 217-219, 222). We recently demonstrated 
that CDK1 phosphorylates 4E-BP1 at canonical sites T37, T46, S65, and T70 during 
mitosis and generates a high molecular weight phospho-isoform called δ-4E-BP1, even 
in the absence of mTOR activity (209). Although we have observed active cap-
dependent translation during mitosis, the function of hyperphosphorylated δ-4E-BP1 
and its contribution to tumorigenesis remain unknown.  
 Here we identify a CDK1 phosphorylation site, S83, that is unique to mitotic δ-4E-
BP1.  4E-BP1 S83 phosphorylation does not participate in regulation of general cap-
dependent translation or eIF4F complex formation. Instead, S83-phosphorylated δ-4E-
BP1 preferentially localizes to mitotic centrosomes and peaks during metaphase.  When 
S83 is substituted with alanine, 4E-BP1.S83A, to prevent δ-4E-BP1 formation, the 
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mutant 4E-BP1 partially inhibits cell transformation induced by the viral oncoprotein 




















3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture and Transfection/Transduction 
293, 293FT, HeLa, U2OS, U87, U251, and Rat-1 cells (ATCC) were maintained in 
DMEM (Corning Cellgro) supplemented with 10% FBS. HCT116 cells (ATCC) were 
maintained in McCoy’s medium (Sigma) supplemented with 10% FBS. 293 and 293FT 
cells were transfected using Lipofectamine 2000 (Invitrogen) and harvested after 48 h. 
Rat-1 cells were transduced by lentiviral infection and harvested after 5-10 days. 
3.2.2 Plasmids 
FLAG-HA-HA tagged 4E-BP1 open reading frame was excised from pBabe HA-4E-BP1 
(170) and cloned into pCMVtag2B vector to generate pCMVtag2B.HA-4EBP1. HA-4E-
BP1 mutants (T37A/T46A, S83A, S83D, S83E, S65A/S101A, T70A, I15A/F114, and 
T37E/T46E/S65E/T70E) were generated from pCMVtag2B.HA-4EBP1 wild type 
construct by the QuikChange Lightning site-directed mutagenesis kit (Agilent 
Technologies). pLVX EF.puro was modified from pLVX-puro vector (Clontech) by 
replacing CMV promoter with elongation factor-1alpha (EF) promoter (170). Codon-
optimized MCV sT and HA-4E-BP1 sequences were inserted into pLVX EF.puro using 
AfeI and SbfI sites. The primers used for each site-directed mutagenesis are listed on 
Table 1, and the plasmids constructs are listed on Table 2. 
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Table 2. Plasmids constructs used for HA-tagged 4E-BP1 and MCV sT expression. 
 
3.2.3 Fluorescence Quantification 
Single channel image generated by fluorescence microscope was opened in ImageJ. 
Each fluorescent cell was selected by in a 45-pixel diameter circle, and the intensity 
value of each circle was measured. Background subtraction was done by subtracting 
the value measured with the same size circle placed on the background of the image. 
3.2.4 In vitro Translation Assay 
TNT quick coupled transcription/translation system was used for in vitro protein 
synthesis per manufacturer instructions (Promega). DNA template for the TNT was 
generated from plasmid pFR_CrVP_xb (Addgene) by primers with a 5’ flanking T7 
promoter sequence as described in the previous chapter (209). Reaction was performed 
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in a 20-μl volume containing 0.5 μg of bicistronic reporter DNA template in the presence 
of varying concentrations of either untreated or CDK1-treated GST or GST-4E-BP1 or in 
the presence of 0.5 μM m7GTP cap-analog (Promega). GST-4E-BP1 or GST alone (2 
μg) was pre-incubated with either 10 units of CDK1/Cyclin B1 (NEB) or 1 μg/mL BSA for 
1 h at 30 °C. Reaction mix was incubated at 30 °C for 1 h. Luciferase assay was 
performed by dual luciferase assay kit (Promega). 
3.2.5 Lentiviral Transduction 
Codon-optimized MCV sT and HA-4E-BP1 sequences were inserted into pLVX EF.puro 
using AfeI and SbfI sites. For lentivirus production, 293FT (Invitrogen) cells were 
transfected with the pLVX lentivirus vector and the two psPAX2 and pMD2.G packaging 
vectors. Lentivirus infection was performed in the presence of 6 μg/ml polybrene. 
Infected cells were selected with puromycin (2 μg/ml). 
3.2.6 Immunoblotting and Antibodies 
Cells were lysed in buffer (50 mM Tris-HCl, pH 7.4; 0.15 M NaCl; 1% Triton X-100; 2 
mM Na3VO4; 2 mM NaF; 0.1% SDS) containing protease inhibitors (Roche). Lysates 
were resolved by 12% (5-20% for cap-binding assay) SDS-PAGE and transferred to 
nitrocellulose. Membranes were blocked with 5% milk in 1X TBS and incubated with 
primary antibodies overnight at 4 °C. Blots were subsequently incubated with IRDye-
labeled anti-rabbit or anti-mouse secondary antibodies and analyzed on the Odyssey 
infrared scanner (LI-COR Biosciences). The following primary antibodies were used in 
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this study: phospho-4E-BP1S83 antiserum, phospho-4E-BP1T70, phospho-4E-BP1S65/S101, 
phospho-4E-BP1T37/T46, total 4E-BP1, phospho-Histone H3S10, eIF4E, eIF4G, eIF4A, γ-
tubulin (Cell Signaling), α tubulin (DSHB), HA (Covance), 800CW goat polyclonal anti-
rabbit IgG, and 680CW goat polyclonal anti-mouse IgG (LI-COR Biosciences). 
3.2.7 Cell Cycle Synchronization 
HeLa, HCT116, U87, U251, U2OS, and 293 cells (ATCC) were synchronized as 
described in the previous chapter (209). 
3.2.8 Kinase Inhibitors 
Active site kinase inhibitors were used in cell culture as follows: 5 μM PP242 (mTOR) 
and 9 μM RO-3306 (CDK1). Proteasome inhibitor MG132 (10 μM) was co-incubated 
with RO-3306 for in vivo CDK1 inhibition. PP242, RO-3306, VX-680 (AURK), and BI-
6727 (PLK1) kinase inhibitors were used at 5 μM for in vitro phosphorylation assays. 
Phospho-Ser83 4E-BP1 Polyclonal Antibody Production. Rabbits were immunized with 
4E-BP1 synthetic phospho-peptide 77TIPGVT(pS)PSSDEP89. Antiserum was 
periodically collected after multiple immunization boosts. 
3.2.9 Flow Cytometry 
Asynchronous U2OS, U87, HeLa, and 293 cells were trypsinized, fixed in 10% buffered 
formalin, and permeabilized with 0.1% saponin in 1% FBS/PBS for 15 min at RT.  Cells 
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were stained with p4E-BP1T37/T46 antibody or rabbit IgG control antibody for 3 h at 
RT. After washing three times with 1% FBS/PBS, cells were reacted with anti-rabbit 
Alexa 488-labeled IgG (Invitrogen) for 1 h at RT. For phospho-histone H3S10 staining, 
cells were permeabilized with 1% FBS/PBS containing 0.25% Triton X-100 for 3 min at 
RT. Alexa 647-labeled pH3S10 antibody (Cell Signaling) or control Alexa 647-labeled 
rabbit IgG (Cell Signaling) were reacted with cells for 1 h at RT. After washing three 
times with 1% FBS/PBS, DNA was stained with 1% FBS/PBS containing 50 μg/mL 
propidium iodide (PI) and 40 μg/mL RNase A (Sigma) for 30 min. For p4E-BP1S83 flow 
cytometry analysis, U2OS and HeLa cells were treated with growth medium containing 
0.5 μM nocodazole or DMSO for 20 h. p4E-BP1S83 antiserum or pre-immune serum in 
1% FBS/PBS were used. Cells were analyzed by the BD Accuri C6TM cell analyzer (BD 
Biosciences). 
3.2.10 Mass Spectrometry 
HeLa cells were disrupted, proteins tryptically digested, phosphopeptide enriched, 
TMT10-labeled, and high mass accuracy LC-MS/MS analyzed as previously described 
(365). Variations include use of TMT10 instead of iTRAQ labeling, cell lysate versus 
tissue disruption, and use of Q Exactive Orbitrap MS. 293 cell LC-MS/MS analyses 
were performed identically, except for quantitation which used label-free approaches as 
previously described (366).   
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3.2.11 Two-Dimensional Electrophoresis 
HeLa cells were lysed in non-denaturing lysis buffer supplemented with protease 
inhibitors (Roche). Lysates were isoelectrically focused as described in the previous 
chapter (209). 
3.2.12 In Vitro Protein Phosphorylation Assay 
Recombinant GST-4E-BP1 was incubated in a reaction containing 1X protein kinase 
buffer (NEB) and mitotic HeLa cell lysate as described in the previous chapter (209). 
3.2.13 Immunofluorescence 
293, HeLa, U2OS, or U87 cells (0.3 x 106) were seeded onto poly-L-lysine treated glass 
coverslips. The next day, cells were washed with ice-cold 1X PBS and fixed with 2% 
paraformaldehyde for 15 min at RT, followed by permeabilization with cold MetOH for 
10 min at -20 °C. Cells were blocked with 10% normal goat serum (Cell Signaling) for 1 
h at RT and then stained with p4E-BP1S83 antiserum pre-absorbed with 
unphosphorylated 77TIPGVTSPSSDEP89, together with γ-tubulin or phospho-histone 
H3S10 antibodies (Cell Signaling) for 2 h at RT. Cells were then washed with cold 1X 
PBS three times for 5 min each and incubated with Alexa 488-labeled anti-rabbit 
secondary antibody and Alexa 568-labeled anti-mouse antibody (Invitrogen) at RT for 1 
h. Cells were examined by fluorescence microscopy (Olympus). Confocal microscopy 
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was performed with Leica TCS SP2 upright confocal microscope. Intensity of 
fluorescence staining was measured by ImageJ.  
3.2.14 m7GTP Cap Binding Assay 
293 were lysed in non-denaturing lysis buffer supplemented with protease inhibitors 
(Roche). Lysates were incubated with m7GTP sepharose beads (Jena Bioscience) as 
described in the previous chapter (209). 
3.2.15 Foci Formation Assays 
Rat-1 cells were infected with recombinant lentiviruses and grown for two weeks in 6-
well plates for foci formation assay. To determine viral titer and establish stable cell 
lines, cells were selected with puromycin (2 μg/ml) for pLVX EF vectors. After two 
weeks, foci were stained with crystal violet (0.025% in 1X PBS), and plates were photo-











3.3.1 δ-4E-BP1 hyperphosphorylation is a feature of mitosis across multiple 
cancer cell lines. 
 
Figure 28. δ-4E-BP1 hyperphosphorylation is a common feature of mitosis across 
multiple cancer cell lines. 
(A) Mitotic arrest of various cancer cell lines induces δ-4E-BP1. 293, HeLa, HCT116, 
U2OS, U87, and U251 cells were arrested for 20 h with DMSO or nocodazole 
(prometaphase). Cells were treated at 16 h with mTOR kinase active-site inhibitor 
PP242 (5 μM). Nocodazole arrest induces PP242-resistant δ-4E-BP1 (black arrowhead) 
in all cell lines tested. (B) pH3S10+ mitotic cells have higher levels of 4E-BP1T37/T46 
phosphorylation than interphase cells. Dual flow cytometry staining for pH3S10 and p4E-
BP1T37/T46 was performed on asynchronous 293, HeLa, U2OS, and U87 cells. Increased 
pH3S10+ fluorescence was correlated to increased p4E-BP1T37/T46+ fluorescence for all 
cell lines. 
 
4E-BP1 has four discernible gel isoforms named α, β, γ, and δ based on ascending 
molecular weight and phosphorylation (157). To determine the generalizability of δ-4E-
BP1 expression during mitosis, six cell lines—293, HeLa, HCT116, U2OS, U87, and 
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U251—were arrested in prometaphase with nocodazole and examined for 4E-BP1 
phosphorylation. Hyperphosphorylated δ-4E-BP1 was the predominant isoform in 
mitotic cells from all cell lines and is resistant to the mTOR inhibitor PP242 (Figure 
28A). Asynchronous cells expressed mainly α, β, and γ 4E-BP1 isoforms that were 
sensitive to mTOR inhibition. Expression of α, β, and γ forms was variably detectable 
and sensitive to PP242 in nocodazole-arrested cells, which is consistent with non-
mitotic cell contamination. In addition, flow cytometry revealed a correlation between 
phospho-4E-BP1T37/T46 (p4E-BP1T37/T46) and mitotic marker phospho-histone H3S10 
(pH3S10), indicating that mitotic cells tend to have a high level of 4E-BP1 
phosphorylation (Figure 28B).  
3.3.2 S83 phosphorylation is a component of δ-4E-BP1 and is mediated by 
CDK1/CYCB.  
The phosphorylation of 4E-BP1 is hierarchical, with mTOR-directed priming 
phosphorylations at T37 and T46 being essential for additional phosphorylations at T70 
and S65 (172). S65 phosphorylation is abundant in the γ-isoform in asynchronous cells 
as well as the higher molecular weight δ-isoform during mitosis (Figure 28A). Lambda 
phosphatase treatment collapses all 4E-BP1 isoforms to the unphosphorylated form 
(209). These data are consistent with the δ-isoform having a unique phosphorylation 
site in addition to phosphorylations at other known sites. To identify additional 
phosphorylation sites responsible for the slower migration of the δ-isoform, HeLa and 
293 cells arrested in mitosis, compared to asynchronous populations, were examined 
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) based quantitative 
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phosphoproteome analysis. The phospho-S83 site represented by the digested peptide, 
74DLPTIPGVT(pS)PSSDEPPMEASQSHLR99, was quantitatively identified only in mitotic 
cells (Figure 29). 
 
Figure 29. LC-MS/MS spectrum for phospho-S83 4E-BP1 peptide identified only in 
mitotic HeLa cells. 
HeLa cells were disrupted, proteins tryptically digested, phosphopeptide enriched, 
TMT10-labeled, and high mass accuracy LC-MS/MS analyzed as previously described 
(365). Variations include use of TMT10 instead of iTRAQ labeling, cell lysate versus 
tissue disruption, and use of Q Exactive Orbitrap MS. 
 
 
 To confirm that phosphorylation at S83 is a bona fide component of the δ-4E-
BP1 isoform, a phospho-specific antibody was raised in rabbits by immunizing with a 
synthetic 4E-BP1 peptide having S83 phosphorylated (77TIPGVT(pS)PSSDEP89). This 
antiserum is specific for phospho-S83 but also has weak reactivity to non-
phosphorylated 4E-BP1 that requires pre-absorption or peptide blocking to reduce. 
Rabbit antiserum was screened by immunoblotting against lysates from asynchronous 
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and mitotic 293 cells expressing HA-tagged 4E-BP1 variants—wild-type, T37A/T46A, 
S65A/S101A, T70A, and S83A. Immunoblotting showed loss of reactivity against only 
4E-BP1.S83A expressed in mitotic cells, confirming the specificity of the antibody 
(Figure 30).  Phosphorylation of endogenous 4E-BP1 at T37, T46, S65, and T70 was 
present in α, β, and γ isoforms in asynchronous HeLa cells but not at S83 (Figure 31A). 
S83 phosphorylation, however, was abundant only in the δ-4E-BP1 isoform of HeLa 
cells arrested with nocodazole. Reactivity of the δ-isoform with the other 4E-BP1 
phospho-specific antibodies in the presence and absence of PP242 indicated that S83 
phosphorylation occurs in addition to phosphorylation at other sites in δ-4E-BP1, and is 
resistant to mTOR inhibition. Asynchronous and mitotic HeLa cell lysates from Figure 
31A were also fractionated by two-dimensional electrophoresis (Figure 31B). S83 
phosphorylation of 4E-BP1 was detected on the slowest-migrating isoelectric focusing 
spot corresponding to δ-4E-BP1 (white arrowheads) and a second spot (black 
arrowheads) below it that is absent in p4E-BP1T37/T46 staining. In addition, a 4E-
BP1.T37A/T46A priming-site mutant protein was phosphorylated at S83 but not at S65 
in mitotic cells, indicating that phosphorylation at S83, in contrast to S65, may not be 
dependent on T37/T46 phosphorylation (Figure 31C). Furthermore, S83 
phosphorylation of 4E-BP1 in mitotic cells was confirmed by flow cytometry staining with 
pH3S10 and p4E-BP1S83 antiserum. U2OS (Figure 31D) and HeLa (Figure 32) cells 
showed p4E-BP1S83 positivity exclusively for pH3S10+ mitotic cells. When U2OS cells 
were arrested with nocodazole (Figure 31D), mitotic cells formed a discrete p4E-




Figure 30. p4E-BP1S83 rabbit antiserum specificity screen against 4E-BP1 
phosphorylation mutants. 
293 cells were transfected with wild-type HA-4E-BP1 and phospho-defective mutants 
T37A/T46A, S65A/S101A, T70A, and S83A and were arrested with nocodazole (0.5 
μM) for 16h and harvested for immunoblotting with p4E-BP1S83 rabbit antiserum. 
Mutation of S83 to alanine eliminated the p4E-BP1S83 signal from nocodazole-arrested 
293 cells (arrow). However, mutations at canonical phosphorylation sites still showed 
the S83 phosphorylation mark despite the relatively faster migration of mutant proteins 
due to the loss of phosphorylation at mutated sites. Slow migrating bands (asterisks) 
may represent minor protein population from triple-tagged vector FLAG-HA-HA-4E-BP1. 








Figure 31. S83 phosphorylation is a component of δ-4E-BP1 and is mediated by 
CDK1/CYCB. 
(A) Polyclonal anti-p4E-BP1S83 rabbit antiserum detects S83 phosphorylation in mitotic 
δ-4E-BP1. HeLa lysates from asynchronous and nocodazole arrest conditions were 
immunoblotted with p4E-BP1S83 antiserum. p4E-BP1S83 was found only in the δ-4E-BP1 
isoform in mitotic cells and was resistant to mTOR inhibition by PP242. (B) HeLa cell 
lysates from (A) were fractionated by isoelectric focusing (pH 3-6), followed by 
immunoblotting with phospho-specific and total 4E-BP1 antibodies. White arrowheads  
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Figure 31 (continued) 
indicate the isoelectric focusing spot corresponding to δ-4E-BP1, and black arrowheads 
indicate a second spot revealed by p4E-BP1S83 staining. (C) Priming-site mutation of 
T37/T46 to alanine does not inhibit S83 phosphorylation during mitosis. Wild-type and 
T37A/T46A mutant HA-4E-BP1 expression plasmids were transfected into 293 cells. 
Cells were arrested for 20 h with DMSO or nocodazole 48 h post-transfection. Cells 
were treated at 16 h with mTOR kinase active-site inhibitor PP242 (5 µM). Mutation of 
4E-BP1 at T37/T46 blocked S65 phosphorylation but did not prevent S83 
phosphorylation during mitosis. (D) pH3S10+ mitotic cells are positive for 4E-BP1S83 
phosphorylation. Dual flow cytometry staining for pH3S10 and p4E-BP1S83 was 
performed on asynchronous and nocodazole-arrested U2OS cells. pH3S10 fluorescence 
was correlated to p4E-BP1S83. (E) CDK1 inhibition by RO-3306 ablates S83 
phosphorylation in mitotic cells. HeLa cells were arrested in G1 by L-mimosine 
treatment and mitosis by nocodazole treatment for 20 h. Cells were subsequently 
treated with kinase inhibitors PP242 (mTOR, 5 μM) and RO-3306 (CDK1, 9 μM) for 4 
hours, supplemented with 10 μM MG132 proteasome inhibitor to prevent mitotic 
exit/slippage. 4E-BP1S83 phosphorylation was abolished by RO-3306 treatment, along 
with δ-4E-BP1, in mitotic cells. Combined PP242 and RO-3306 erased most mitotic 4E-
BP1 phosphorylation in these cells. S83 phosphorylation and δ-4E-BP1 were absent in 
G1-arrested cells, as expected. (F) Mitotic lysate phosphorylates GST-4E-BP1 at S83. 
Mitotic HeLa cell lysates enriched by nocodazole arrest were incubated with GST-4E-
BP1 and reacted in buffer containing 200 μM ATP for 30 min at 30 °C in the presence or 
absence of mTOR (PP242), RO-3306 (CDK1), VX-680 (AURK A/B/C), and BI-6727 
(PLK1) kinase inhibitors (5 μM). GST-4E-BP1 was phosphorylated at S83 and the other 
known regulatory sites. CDK1 inhibition by RO-3306 treatment reduces S83 
phosphorylation, consistent with the other phosphorylation sites. Treatment with kinase 
















Figure 32. p4E-BP1S83 flow cytometry staining of HeLa cells. 
Dual flow cytometry-stained pH3S10+ mitotic HeLa cells are positive for p4E-BP1S83. 
 
We have previously shown that proline-directed, serine/threonine kinase 
CDK1/CYCB phosphorylates 4E-BP1 during mitosis at T37/T46, S65/S101, and T70, all 
which share the minimal consensus S/T-P sequence (209, 367). To determine whether 
CDK1 also phosphorylates S83, HeLa cells were arrested in G1 by L-mimosine 
treatment or in mitosis by nocodazole treatment and then treated with CDK1 active site 
inhibitor RO-3306, supplemented with MG132 proteasome inhibitor to prevent mitotic 
slippage (345, 368). CDK1 inhibition by RO-3306 abolished S83 phosphorylation and δ-
4E-BP1 formation, in addition to reducing phosphorylation at the other phosphorylation 
sites (Figure 31E). G1-arrested cells had low levels of phosphorylated 4E-BP1 that was 
sensitive to mTOR inhibition by PP242 but insensitive to RO-3306 (347). To confirm 
whether CDK1 directly phosphorylates S83, recombinant GST-4E-BP1 was mixed with 
mitotic HeLa lysate in an in vitro phosphorylation assay. Mitotic lysate phosphorylated 
GST-4E-BP1 at S83, which was reversed by addition of RO-3306 but not of PP242, VX-
680 (pan-AURK inhibitor), or BI-6727 (PLK1 inhibitor) (Figure 31F). Taken together, 
these findings demonstrate that CDK1 phosphorylates 4E-BP1 at S83 during mitosis. 
 106 
3.3.3 S83-phosphorylated 4E-BP1 colocalizes with centrosomes during mitosis 
and peaks at metaphase. 
S83 phosphorylation of 4E-BP1 in mitotic cells was also confirmed by 
immunofluorescence microscopy. Staining of 293 (Figure 33A), HeLa, U87, and U2OS 
(Figure 34) cells showed p4E-BP1S83 positivity in all mitotic cells, which are also 
positive for pH3S10, with the exception of telophase cells whose chromosomes are 
decondensed and hence negative for pH3S10 (369). In addition to a diffuse staining 
pattern in mitotic cells, p4E-BP1S83 also formed two distinct puncta near condensed 
chromosomes, which colocalized with centrosomal marker γ-tubulin as detected by 
confocal microscopy (Figure 33B). To show that this binding is phospho-specific, we 
performed a phospho-peptide competition assay for the staining (Figure 35A). These 
data suggest that a portion of p4E-BP1S83 may colocalize with centrosomes during 
mitosis. To further dissect the kinetics of mitotic 4E-BP1 S83 phosphorylation, 
asynchronous 293 cells were counted in each of the phases of mitosis (pH3S10+) and in 
interphase (pH3S10-) based on their morphology and chromosome condensation. pH3S10 
is present throughout mitosis but declines in telophase due to chromosome 
decondensation (369), and p4E-BP1S83 is low in prophase, peaks at metaphase, and 
also declines in telophase (Figure 33C). Cells were also stained for p4E-BP1T37/T46 and 
did not exhibit substantial differences across most phases (Figure 36). Altogether, 
these data demonstrate that the phosphorylation of 4E-BP1 at S83 is regulated 
throughout mitosis.  
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Figure 33. S83-phosphorylated 4E-BP1 colocalizes with centrosomes during 
mitosis and peaks at metaphase. 
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Figure 33 (continued) 
(A) Immunofluorescence staining shows the presence of p4E-BP1S83 only in mitotic 
cells. Asynchronous 293 cells were fixed, and dual-stained with p4E-BP1S83 antiserum 
(green) and pH3S10 (red) antibodies. Nuclear DAPI stain is shown in blue. (B) p4E-
BP1S83 staining colocalizes with γ-tubulin staining to centrosomes in mitotic nuclei of 
293 cells. Asynchronous 293 cells were fixed and dual-stained with p4E-BP1S83 
antiserum (green) and γ-tubulin (red) antibodies. Nuclear DRAQ5 stain is shown in blue. 
Stained cells were observed by confocal microscopy for colocalization studies. (C) 4E-
BP1 S83 phosphorylation peaks at metaphase and declines in telophase. 
Asynchronous 293 cells were fixed and dual-stained with p4E-BP1S83 antiserum (green) 
and pH3S10 (red) antibodies. Nuclear DAPI stain is shown in blue. Cells in interphase 
and in different phases of mitosis (prophase, metaphase, anaphase, and telophase) 
were identified by morphology and chromosome condensation. Intensity of p4E-BP1S83 
staining for cells in each phase was quantified by ImageJ. Thirty cells for each phase 








Figure 34. p4E-BP1S83 immunofluorescence staining of U2OS cells. 
U2OS cells were arrested and released as in Figure 30, fixed, and dual-stained with 
p4E-BP1S83 antiserum (green) and pH3S10 (red) antibodies. Nuclear DAPI stain is 
shown in blue. Immunofluorescence staining shows the presence of p4E-BP1S83 only in 
pH3S10+ mitotic cells. Similar results were obtained with HeLa and U87 cells. p4E-








Figure 35. Epitope competition assays with antigen pre-absorbed p4E-BP1S83 
antiserum. 
(A) Confocal microscopy staining of 293 cells with phosphorylated peptide and non-
phosphorylated peptide pre-absorbed p4E-BP1S83 antiserum. p4E-BP1S83 antiserum 
was incubated with non-phosphorylated (non-phospho) or phosphorylated (phospho) 
4E-BP1 S83 peptide (77TIPGVTSPSSDEP89) prior to immunofluorescence staining and 
confocal microscopy. Asynchronous 293 cells were fixed and dual-stained with p4E-
BP1S83 antiserum (green) and γ-tubulin (red) antibodies. Nuclear DRAQ5 stain is shown 
in blue. Non-phosphorylated peptide pre-absorbed p4E-BP1S83 staining colocalizes with 
γ-tubulin staining to centrosomes, which is ablated with phosphorylated peptide 
preabsorption. (B) Immunoblotting staining of unreacted and phosphorylated GST-4E-
BP1 with dephosphorylated GST-4E-BP1 pre-absorbed p4E-BP1S83 antiserum. p4E-
BP1S83 antiserum was incubated with lambda phosphatase-treated GST-4E-BP1 and 
purified with glutathione sepharose beads prior to immunoblotting staining. 
Dephosphorylated GST-4E-BP1 pre-absorbed p4E-BP1S83 antiserum stains only GST-
4E-BP1 phosphorylated by mitotic HeLa cell lysate. 
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Figure 36. p4E-BP1T37/T46 phosphorylation is maintained during interphase and 
mitosis. 
Asynchronous 293 cells were fixed and dual-stained with p4E-BP1T37/T46 (green) and 
pH3S10 (red) antibodies. Nuclear DAPI stain is shown in blue. Cells in interphase and in 
different phases of mitosis were identified by morphology and chromosome 








3.3.4 Mutation of 4E-BP1 at S83 does not affect general cap-dependent 
translation but partially reverses MCV sT-induced Rat-1 cell transformation. 
4E-BP1 possesses an amino acid motif necessary for interaction with eIF4E, containing 
the sequence 54YDRKFLM60 (100). The consensus binding motif Y(X)4LΦ (where X is 
any amino acid residue and Φ is a hydrophobic residue) is shared by other 4E-BPs and 
translation initiation factor eIF4G. Recently, a C-terminal loop region of 4E-BP1, 
79PGVTS83, was reported to also play an auxiliary role in binding eIF4E at a 
hydrophobic pocket separate from the canonical 54YDRKFLM60 binding pocket (105, 
106, 370, 371). If S83 phosphorylation destabilizes this auxiliary domain, it may affect 
4E-BP1:eIF4E interaction and cap-dependent initiation and translation. 
 To assess this, in vitro translation reactions were performed using using TNT 
transcription/translation coupled system using a bicistronic reporter with a firefly 
luciferase gene driven by cap-dependent translation followed by a renilla luciferase 
gene driven by cricket paralysis virus (CrPV) IRES-mediated translation. Recombinant 
GST-tagged 4E-BP1.S83A decreased cap-dependent translation to similar levels as 
wild-type GST-tagged 4E-BP1, and CDK1 phosphorylation of this protein rescued 
translation (Figure 37A). GST-4E-BP1.T37A/T46A having substitutions at priming sites 
inhibited translation despite CDK1 treatment. IRES-mediated translation, however, was 
unaffected by GST-4E-BP1 as expected (Figure 37B). Similarly, 4E-BP1.S83A had no 
detectable effect on m7GTP cap resin pull-down assays compared to wild-type 4E-BP1 
protein (372). Compared to wild-type 4E-BP1, S83A, (or phosphomimetic mutants S83D 
and S83E) did not differ significantly in binding cap-bound eIF4E and did not 
significantly affect cap-complex formation, as measured by eIF4G and eIF4A pull-down 
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(Figure 38A). Unlike 4E-BP1.S83A, phosphorylation-defective and mTORC1 binding 
mutants (T37A/T46A and I15A/F114A) efficiently inhibited eIF4G binding to eIF4E and 
in vitro cap-dependent translation (100, 164, 165, 167), suggesting that S83 
phosphorylation does not play a significant role in general cap-dependent translation 
regulation. 
MCV sT transforms Rat-1 and NIH3T3 cells through a novel mechanism 
requiring 4E-BP1 phosphorylation that can be reversed by expression of a constitutively 
active 4E-BP1.T37A/T46A mutant (170, 209). To determine whether S83 
phosphorylation is required for the transformation activity of this viral oncoprotein, we 
performed foci formation assays with Rat-1 co-expressing MCV sT and 4E-BP1 
variants. Cells were first stably transduced with empty vector, wild-type 4E-BP1, 4E-
BP1.T37A/T46A, 4E-BP1.I15A/F114A, or 4E-BP1.S83A, followed by transduction with 
empty vector or MCV sT. MCV sT transformed Rat-1 cells expressing either empty-
vector control or wild-type 4E-BP1, and this was reversed by co-expression of non-
phosphorylatable 4E-BP1.T37A/T46A and 4E-BP1.I15A/F114A mutant proteins (Figure 
38B). 4E-BP1.S83A mutant expression partially but reproducibly decreased sT-induced 
transformation to ~51% of empty vector control and ~66% of wild-type 4E-BP1. 
Immunoblotting of lysates from these cells show comparable protein levels of wild-type 
4E-BP1 and 4E-BP1.S83A; therefore, the negative effect on foci formation did not result 
from enhanced expression of the latter (Figure 39). Low protein levels were predictably 
observed for 4E-BP1.T37A/T46A and 4E-BP1.I15A/F114A mutants because they inhibit 




Figure 37. Mutation of 4E-BP1 at S83 does not affect general cap-dependent 
translation initiation complex formation. 
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Figure 37 (continued) 
In vitro cap-dependent translation is not inhibited by blocking S83 phosphorylation. A 
bicistronic luciferase reporter was used in a TNT quick coupled transcription/translation 
system to produce firefly and renilla luciferase through cap-dependent and cricket 
paralysis virus (CrPV) IRES-mediated translation, respectively. (A) Addition of GST-4E-
BP1 wild-type or S83A mutant decreased translation to similar levels; however, when 
these were phosphorylated by CDK1 in kinase buffer, translation was rescued. Addition 
of unphosphorylatable GST-4E-BP1 T37A/T46A inhibited translation even when reacted 
with CDK1. Translation was unaffected by GST protein alone. Cap-dependent 
translation specific inhibition by m7GTP cap analog incubation was used as a negative 
control. Luciferase activity was measured in relative light units (RLU). (B) IRES cap-
independent translation using a CrPV IRES renilla luciferase reporter was unaffected by 
addition of GST-4E-BP1 as expected. (C) Recombinant GST-4E-BP1 and GST protein 




Figure 38. Mutation of 4E-BP1 at S83 does not affect general cap-dependent 
translation initiation complex formation but partially reverses MCV sT-induced 
Rat-1 cell transformation. 
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Figure 38 (continued) 
(A) eIF4F cap-binding is not affected by S83 phosphorylation. 293 cells were 
transfected with wild-type HA-tagged 4E-BP1 and mutants T37A/T46A, S83A, S83D, 
S83E, I15A/F114A, and T37E/T46E/S65E/T70E (EEEE). After 48 h, cells were treated 
with DMSO or nocodazole for 20 h and harvested. Cell lysates were either directly 
immunoblotted (input) or mixed with m7GTP coupled sepharose beads, precipitated, 
and immunoblotted. S83A, S83D, and S83D mutants did not differ from wild-type 4E-
BP1 in their binding to cap-bound eIF4E and did not affect eIF4G and eIF4A association 
to eIF4E. HA-4E-BP1 phosphorylation mutant T37A/T46A and mTORC1-binding mutant 
I15A/F114A reduced eIF4G and eIF4A binding, whereas the opposite pattern was found 
for negative control phosphomimetic mutant EEEE. Comparable amounts of eIF4G and 
eIF4A were pulled down with m7GTP beads for both asynchronous and mitotic cells. (B) 
A representative foci formation assay with the MCV sT viral oncoprotein in Rat-1 cells 
stably expressing HA-tagged 4E-BP1 wild type (WT), T37A/T46A, I15A/F114A, S83A 
mutants, and empty vector. Foci formed two weeks after MCV sT lentivirus transduction 
were stained with 0.5% crystal violet. Crystal violet staining intensity was measured 
using the LICOR infrared scanner. For each stable cell line, crystal violet staining 
intensity of empty vector-transduced cells was subtracted from that of sT-transduced 
cells, and relative intensity to empty vector control was determined for each HA-4E-BP1 








Figure 39. Expression of HA-tagged 4E-BP1 in Rat-1 cells used for transformation 
assays. 
Rat-1 cells stably transduced with HA-tagged 4E-BP1 wild type (WT), T37A/T46A, 
I15A/F114A, S83A mutants, and empty vector were harvested prior to transformation 
assays and subjected to immunoblotting. Protein levels of WT and S83A-mutated 4E-
BP1 were comparable, while expression of non-phosphorylatable mutants T37A/T46A 














During mitosis, 4E-BP1 is hyperphosphorylated, rendering it inactive as a cap-
dependent translation gate keeper (209). Our current studies show that S83-
phosphorylated δ-4E-BP1 is specific to mitosis and is a result of CDK1 activity.  When 
S83 is mutated to a non-phosphorylatable alanine, no changes in cap-binding or cap-
dependent translation were detected. Instead, loss of this phosphorylation site partially 
reverses cell transformation caused by MCV small T oncoprotein. Unlike α-γ 
phosphorylated 4E-BP1 isoforms, δ-4E-BP1 preferentially accumulates at centrosomes 
during mitosis. Unlike 4E-BP1 phosphorylation by mTOR kinase at canonical sites, 
CDK1 phosphorylation of 4E-BP1 at S83 may lead to a gain-of-function for this 
hyperphosphorylated protein (Figure 40).  
 
Figure 40. Novel mitosis-specific phosphorylation of 4E-BP1 Ser83 by CDK1. 
 
 Our findings confirm previous studies showing δ-4E-BP1 expression in multiple 
cell lines synchronized in mitosis by chemical or mechanical means (207, 208). 
Treatment with nocodazole, a microtubule-destabilizing drug, induced δ-4E-BP1 across 
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all cell lines. While mTOR inhibition by PP242 eliminates most phosphorylated 4E-BP1 
isoforms in asynchronous cells, it does not affect δ-4E-BP1. The appearance of α, β, 
and γ forms of 4E-BP1 in nocodazole-arrested cells is likely due to interphase cell 
contamination resulting from differences in synchronization efficiency between cell lines. 
This would explain their sensitivity to PP242 treatment. As predicted by immunoblotting, 
flow cytometry analysis of all cell lines tested shows that pH3S10+ mitotic cells exhibit 
higher levels of p4E-BP1T37/T46+ than pH3S10- interphase cells.  
 Because of its low abundance in asynchronous cells, S83 phosphorylation has 
not been thus far amenable to investigation in contrast to the canonical mTOR-
regulated sites—T37, T46, S65, and T70 (154). We hypothesized that δ-4E-BP1 from 
mitotic cells has additional phosphorylation sites that have been missed in previous 
analyses where mitotic cells comprise less than 1% of all cells in bulk culture. We 
subjected interphase (mitosis-depleted) and mitotic (mitosis-enriched) HeLa and 293 
cells for mass spectrometric analysis, and although our results were not quantitative, we 
identified S83 phosphorylation exclusively in mitotic cells. Mutation of mTOR priming 
sites T37A/T46A did not inhibit S83 phosphorylation in mitotic cells, suggesting that S83 
targeting may not rely on mTOR activity as also evidenced by PP242-mediated mTOR 
inhibition. Our epitope-tagged 4E-BP1 construct does not migrate the same way as 
endogenous 4E-BP1 and makes it difficult to assess each phospho-isoform discretely. 
Nonetheless, we are confident that the highest molecular weight form of HA-tagged 4E-
BP1 induced during mitosis represents δ-4E-BP1.  
By generating a polyclonal antibody against p4E-BP1S83, we were able to confirm 
that δ-4E-BP1 is phosphorylated at S83 and that this antibody can be used as a mitotic 
 121 
marker for immunoblotting, immunofluorescence, and flow cytometry. We were also 
able to localize a portion of S83-phosphorylated 4E-BP1 at the centrosomes consistent 
with a previous report, which shows that 4E-BP1 knockdown leads to multipolar 
spindles and misaligned chromosomes (210). Further, S83 phosphorylation increased 
from prophase to metaphase and decreased thereafter, which is in agreement with 
nocodazole synchronization results and with the timing of CDK1 activity (367). 
The p4E-BP1S83 antibody also enabled us to determine that CDK1 is the first 
kinase known to phosphorylate 4E-BP1 at the five phospho-residues (T37, T46, S65, 
T70, and S83) conserved in all three 4E-BPs—4E-BP1, 2, and 3 (144). The polyclonal 
p4E-BP1S83 antiserum has cross-reactivity against non-phosphorylated S83 that 
requires pre-absorption or peptide blocking, which would explain why unreacted GST-
4E-BP1 can still be detected in our in vitro phosphorylation assays. However, the 
substantial increase in p4E-BP1S83 signal in ATP-supplemented reactions confirms our 
in vivo results. Epitope competition assay with dephosphorylated GST-4E-BP1 also 
shows that the antiserum is specific for S83-phosphorylated 4E-BP1 (Figure 35B). 
Nevertheless, all immunofluorescence colocalization studies were performed using 
antiserum pre-absorbed with non-phosphorylated peptide 77TIPGVTSPSSDEP89. 
 Others have reported and established modulation of cap-dependent translation 
through 4E-BP1 phosphorylation at mTOR-targeted sites. Using in vitro translation and 
m7GTP cap-affinity pulldown assays, we do not find general cap-dependent translation 
regulation by 4E-BP1 S83 phosphorylation. However, we cannot exclude the possibility 
that mRNA subpopulations might be regulated at the translational level by S83-
phosphorylated 4E-BP1, such as terminal oligopyrimidine tract (TOP)-containing 
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mRNAs that are reported to be translationally active during mitosis (208). A recent study 
shows that the interaction be-tween the C-terminal loop with eIF4E is required for eIF4F 
complex formation and translation repression in vivo using 4E-BP1 truncation mutants, 
which, in light of our results, prompts the examination of other loop residues (105). 
Expression of full-length 4E-BP1 constructs with mutations at canonical and non-
canonical eIF4E binding motifs would provide robust evidence for this phenomenon in 
cells. 
 Overexpression of constitutively active 4E-BP1 or 4E-BP2 antagonizes cell 
transformation induced by eIF4E, v-Src, H-Ras, and MCV sT expression, indicating that 
4E-BP1 acts as a tumor suppressor (170, 223, 373). Expression of S65A and T70A 
have also been reported to decrease CREF colony formation, but these results were not 
confirmed in the presence of an oncogene (374). Our work showing partial reversal of 
sT-mediated foci formation suggests that 4E-BP1 phosphorylation site S83 contributes 
to that MCV sT cell transformation activity. sT transformation is eliminated by a raptor-
binding mutant of 4E-BP1 (164, 165, 167), suggesting that mTOR and CDK1 
cooperatively promote sT-induced cell transformation. These findings hint at the 
possibility that this residue is also permissive for cell transformation induced by other 
oncoproteins. 
 Hyperphosphorylation of 4E-BP1 in various cancers has been strongly 
suggestive of uncontrolled protein synthesis. However, our study provokes a 
reassessment of the role of 4E-BP1 in cells, particularly during mitosis. It is possible that 
the S83-phosphorylated δ-4E-BP1 isoform has a previously undescribed gain-of-
function role in mitosis. 
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4.0  CONCLUSION AND PERSPECTIVES 
The work presented in this dissertation provokes a reexamination of mitotic cap-
dependent translational control and raises the possibility for novel functions and 
regulation of the translation repressor protein 4E-BP1 (177, 209). mRNA translation has 
been assumed to be repressed during mitosis, until recent studies, including the ones in 
the previous chapters, have come to challenge this dogma (177, 207-209, 243). In 
previous studies, cells had been arrested in mitosis using microtubule destabilizers, 
which inadvertently inhibited cap-dependent translation. As the number of studies that 
use cell cycle synchronization methods that do not affect mRNA translation increases, 
the old paradigm will have to shift (243). This work also raises the hypothesis that cap-
dependent mRNA translation is activated during mitosis to allow for the synthesis of 
proteins required for re-entry into the cell cycle. In tumorigenesis, it is feasible that the 
increased mitogenesis of cancer cells facilitates the translation of proto-oncogenes 
during mitosis, especially those encoded by tumor viruses like MCV. This work indicates 
that one of the principal events in this process is the hyperphosphorylation-inactivation 
of 4E-BP1 by the mitotic CDK1 kinase. 
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4.1 CDK1 REGULATION OF CAP-DEPENDENT TRANSLATION 
Apart from challenging the mitotic translation dogma, this work identified a novel 
pathway that regulates cap-dependent mRNA translation through the mitotic CDK1 
kinase. CDK1 takes over for mTOR kinase to activate cap-dependent mRNA translation 
by targeting 4E-BP1. CDK1 phosphorylates the canonical mTOR-regulated sites T37, 
T46, S65, and T70 of mitotic δ-4E-BP1 and also the novel S83 during mitosis. CDK1-
inhibition by RO-3306 treatment in vivo and in vitro ablates δ-4E-BP1 phosphorylation at 
all sites. Interestingly, S83 phosphorylation is independent of priming T37/T46 
phosphorylation, unlike S65 and T70, which indicates that CDK1 phosphorylates 4E-
BP1 in a unique mode that is different from mTOR. 
A recent report also indicates that cap-dependent translation is regulated in a 
similar manner during meiosis of human, mouse, and bovine oocytes (375). Although 
the authors claim that CDK1 activates mTOR to phosphorylate 4E-BP1 at S65 and T70 
in this study, their data also suggest that CDK1 directly phosphorylates meiotic 4E-BP1, 
in line with our studies on mitotic 4E-BP1 and those of other groups (177, 207-209, 
243). This is perhaps a common translation regulatory pathway in general cell division. 
Moreover, these results encourage further investigation to determine whether other 
CDKs regulate mRNA translation in other phases of the cell cycle. Identifying non-
canonical, alternative pathways for cap-dependent mRNA translation regulation may 
explain resistance to mTOR-targeted therapies in cancer.  
In addition, this work also hints at the existence of novel translational functions 
for 4E-BP1. Recent structural studies have shown that human eIF4E binds 4E-BP1 not 
only through its canonical dorsal surface, but also through its lateral surface. Both 
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human eIF4G and 4E-BP1 compete for dorsal eIF4E binding through their conserved 
YXXXXLΦ binding motif (103). 4E-BP1, however, has been shown to possess a 
secondary eIF4E-binding motif, 79PGVTS83, that forms a loop structure that contacts the 
lateral surface of eIF4E (Figure 41) (105-107, 370). S83 phosphorylation of 4E-BP1 
may regulate the interaction of this loop with the lateral pocket of eIF4E, which may 
allosterically modulate the occupancy of eIF4G at the dorsal pocket. Whether eIF4G 
interacts with this non-canonical pocket on eIF4E remains unclear, as differences in 
protein solubilizing methods have yielded conflicting results (106, 107, 376).  
 
Figure 41. 4E-BP1 S83 is part of the loop binding the lateral pocket of eIF4E. 
The secondary eIF4E binding site of 4E-BP1 (residues in red), composed of residues 
79PGVTS83, makes hydrophobic contacts and hydrogen bonds with the eIF4E residues 
(in blue) within its lateral binding surface (Modified from Sekiyama et al. 2015 (105)). 
 
Therefore, in this dissertation the effects of S83 phosphorylation on cap-
dependent translation regulation by 4E-BP1 were also investigated. In vitro translation 
reactions with a recombinant GST-4E-BP1 S83A mutant did not affect cap-dependent 
translation compared to wild-type 4E-BP1. Cap-binding assays that measure translation 
initiation complex formation in cells did not show a significant difference between wild-
type 4E-BP1 and the S83A mutant. This was unexpected in light of the presence of S83 
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on the secondary eIF4E binding motif recently identified on 4E-BP1. Interestingly, MCV 
sT-induced cell transformation of Rat1 cells was partially reversed by expression of the 
4E-BP1 S83A mutant. Although no significant change in global cap-dependent mRNA 
translation was observed, these results suggest that S83 phosphorylation contributes to 
MCV sT-induced transformation. 
It cannot be ruled out, however, that 4E-BP1 S83 phosphorylation modulates the 
translation of mRNA subpopulations with different 5’ UTR compositions. Ribosomal 
profiling studies have identified that mRNAs that contain a terminal oligopyrimidine 
(TOP) tract in their 5’ UTR are regulated by mTORC1 and are associated with 
increased 4E-BP1 phosphorylation (79, 80). Interestingly, TOP-containing mRNAs 
encoding ribosomal proteins and translation factors have also been reported to be 
actively translated during mitosis (244). It is possible that CDK1, instead of mTOR, 
activates the translation of these messages during mitosis. During mitosis, 4E-BP1 is 
phosphorylated by CDK1 near its canonical and non-canonical eIF4E binding motifs. In 
interphase, on the other hand, 4E-BP1 is not phosphorylated at the non-canonical loop 
containing S83, with which it could exert some inhibitory impact on eIF4E and mRNA 
translation that is absent during mitosis. Thus, 4E-BP1 S83 phosphorylation may 
regulate the translation of mRNA subpopulations, such as those containing TOP motifs, 
which can be distinguished from global mRNA translation using ribosomal profiling. 
Recent studies, however, have identified the La-related protein 1 (LARP1) as the main 
regulator of TOP mRNA translation in asynchronous cell populations (377). LARP1 
binds the 5’ cap of TOP messages and thus blocks eIF4F complex assembly (378). 
Activated mTORC1 sequesters LARP1 through its Raptor subunit to activate TOP 
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mRNA translation (379), which would explain the observed decreased translation of 
TOP mRNAs upon mTORC1 inhibition in the ribosomal profiling studies. Whether CDK1 
or 4E-BP1 substitute for or work with LARP1 during mitosis remains to be explored. 
4.2 S83-PHOSPHORYLATED 4E-BP1 AND MITOTIC TRANSIT 
This work also demonstrates that δ-4E-BP1 is a common feature of mitotic cells. 
Multiple cancer cell lines that were arrested in mitosis expressed the δ-4E-BP1 
phospho-isoform, which was unaffected by treatment with the mTOR inhibitor PP242. 
These mitotic cells had the highest level of 4E-BP1 phosphorylation as compared to 
corresponding interphase cells, supporting the notion that 4E-BP1 is fully inactivated 
during mitosis. Mass spectrometry analysis of 293 and HeLa cells identified a non-
canonical phospho-S83 4E-BP1 peptide found only in mitotic cells, which led to the 
generation of a rabbit polyclonal antibody against this phospho-peptide. When tested by 
immunoblotting, the antibody recognized only δ-4E-BP1 in mitotic cell lysates, showing 
that S83 phosphorylation is a component of this phospho-species. Dual flow cytometry 
staining for mitotic marker phospho-S10 histone H3 and phospho-S83 4E-BP1 
confirmed that only mitotic cells express S83-phosphorylated 4E-BP1.  
Immunofluorescence assays also demonstrated that phospho-S83 4E-BP1 is a 
unique marker of mitotic cells by co-staining with phospho-S10 histone H3. S83 
phosphorylation is low in prophase, peaks at metaphase, and declines in telophase, 
which is consistent with the timing of CDK1 activity (345) (Figure 42). Confocal 
microscopy showed that a fraction of phospho-S83 4E-BP1 colocalizes with 
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centrosomal protein γ-tubulin in mitotic cells. The presence of S83-phosphorylated 4E-
BP1 at centrosomes provides clues on a potential novel function for δ-4E-BP1 during 
mitosis, such as regulating centrosome function. Sheng et al. also reported that 4E-BP1 
localizes at centrosomes and plays a role in maintaining normal mitotic transit (210). 
Interestingly, abnormal spindle formation is observed when 4E-BP1 is depleted (210). 
The aforementioned study on mammalian oocytes shows that 4E-BP1 phosphorylated 
at S65 colocalizes with centrosomes and 4E-BP1 phosphorylated at T70 colocalizes 
with spindle fibers (375). Spindle defects are also observed in meiotic cells expressing a 
non-phosphorylatable 4E-BP1 mutant (375). These findings suggest that 4E-BP1 
serves an important role in cell division of somatic and germ cells alike, where S83 
phosphorylation might be a critical switch in this process. 
 
Figure 42. S83-phosphorylated 4E-BP1 is a novel mitotic marker. 
This diagram shows the cell cycle timing of phospho-S83 4E-BP1 (green) compared to 
that of mitotic markers phospho-S10 histone H3 (purple) and cyclin B (blue). Phospho-
S83 4E-BP1 is not present in interphase centrosomes (red dots) but colocalizes with 
mitotic centrosomes (yellow dots). 
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4.3 TUMOR VIRUS INDUCTION OF MITOTIC TRANSLATION 
Human tumor viruses have been shown to manipulate the cell cycle by targeting mitotic 
E3 ligases in order to enhance the expression and stability of their own proteins. Four 
human tumor viruses—HBV, HTLV-1, HPV, and MCV—encode proteins that have no 
role in infection (Tax, X, E2, and sT, respectively) but target the mitotic anaphase-
promoting complex/cyclosome (APC/C) checkpoint (380). The Merkel cell polyomavirus 
(MCV) viral oncoprotein small T antigen (sT) inhibits the APC/C cdc20 E3 ligase and 
promotes mitotic arrest, similar to the cellular APC/C inhibitor Emi1 (209, 245). In 
addition, MCV sT induces the hyperphosphorylation and inactivation of cap-dependent 
translation inhibitor 4E-BP1 during mitosis, which is required for the transforming activity 
of MCV sT (170). While mTOR regulates 4E-BP1 during interphase, MCV sT-activated 
mitotic kinase CDK1 hyperphosphorylates 4E-BP1 to generate the high molecular 
weight δ-4E-BP1 phospho-isoform. Studies with MCV sT revealed that cap-dependent 
translation is active during mitosis and suggest that mRNA translation is regulated at 
different phases of the cell cycle. In support of this notion, recent studies have shown 
that translation of APC/C inhibitor Emi1 is repressed during mitosis (245), while TOP-
containing mRNAs are actively translated in this phase of the cell cycle (244). 
This work opens up the possibility that the cell cycle is coupled to the regulation 
of translation, in addition to transcription. MCV appears to manipulate the cell cycle by 
targeting APC/C, possibly to promote a state where cap-dependent translation remains 
active even in mitosis. As a consequence, synthesis of viral proteins would proceed 
unhindered, yet this manipulation may also inadvertently lead to unscheduled, abnormal 
mitosis and tumorigenesis. S83-phosphorylated δ-4E-BP1 may be contributing to 
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malignant transformation during viral APC-targeting induced mitosis. Other viruses, 
such as adenovirus, orf virus, CAV, and HCMV, have also been reported to target APC 
(380). Just as some viruses induce S phase entry to replicate their DNA, some may also 
induce mitotic entry to translate their mRNA.  
4.4 FUTURE DIRECTIONS 
Collectively, the studies presented in this dissertation describe a novel regulatory 
mechanism for cap-dependent mRNA translation during mitosis. Future work to 
understand this mechanism will focus primarily on the following objectives: 1) identifying 
mRNAs that are preferentially translated during mitosis through CDK1 phosphorylation 
of 4E-BP1 and 2) determining whether 4E-BP1 S83 phosphorylation modulates its 
interaction with the lateral surface of eIF4E and affects mitotic spindle function.  
To address the first research objective, RNA-immunoprecipitation-coupled 
sequencing (RIP-seq) and ribosomal profiling analyses will be employed (381, 382). 
Through RIP-seq analysis, mRNAs that co-purify with endogenous 4E-BP1 from 
interphase and mitotic cells will be identified and compared. Given the possibility that 
S83 phosphorylation may abolish the interaction between 4E-BP1 and eIF4E, 
transcripts that are translationally activated by this S83 modification during mitosis are 
expected to co-purify with 4E-BP1 from interphase cells, where they are translationally 
repressed. To confirm these results, ribosomal profiling will be used as in previous 
studies (244, 245) to identify ribosome-protected, translationally active mRNAs from 
interphase and mitotic cells. Additionally, ribosomal profiling studies will examine 
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translation regulation by 4E-BP1 S83 mutants. For this purpose, 4E-BP1 knockout cell 
lines will be used to stably express wild-type 4E-BP1 and phospho-defective and 
phospho-mimetic S83 mutants. It is anticipated that differences in translation of mRNAs 
across wild-type and S83 mutant cell lines will reflect differences observed in mitotic 
and interphase parental cell populations. Through these studies, mRNA subpopulations 
that are regulated by CDK1 through 4E-BP1 phosphorylation will be identified, and it is 
expected that some of these genes may contribute to tumorigenesis. 
To address the second objective, pull-down assays will be used to investigate the 
interaction of the 4E-BP1 79PGVTS83 binding motif with eIF4E, and immunofluorescence 
assays will be used to investigate the connection between 4E-BP1 and mitotic spindle 
function. The 7-methyl-guanine cap pull-down assays shown in the previous chapter 
showed that 4E-BP1 S83 phosphorylation mutants did not differ significantly from the 
wild-type protein in their interaction with cap-bound eIF4E. Immunoprecipitation and 
tandem-affinity purification (TAP) assays will be used to pull down wild-type 4E-BP1 and 
S83 mutants directly to determine whether there are indeed no significant differences 
between these proteins (383). 4E-BP1 mutants that cannot bind eIF4E through its 
dorsal surface, with alanine mutations at Y54 and L59, will be included to confirm these 
results. To determine the role of 4E-BP1 in mitotic spindle function, 4E-BP1 knockout 
cell lines will also be used as in the previous objective. Immunofluorescence assays 
staining for tubulin will show any differences in spindle assembly across mitotic cells 
expressing wild-type 4E-BP1 and S83 phosphorylation mutants. It is expected that cells 
expressing 4E-BP1 S83A will exhibit spindle defects similar to studies in oocytes (375). 
All in all, these experiments will hopefully uncover novel functional aspects of 4E-BP1. 
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